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ROLES OF AUTISM GENE ARID1B IN MURINE BRAIN
DEVELOPMENT AND BEHAVIOR
Amanda L. Smith, Ph.D.
University of Nebraska, 2019
Supervisor: Woo-Yang Kim, Ph.D.
Autism spectrum disorder (ASD) and intellectual disability (ID) are highly
prevalent neurodevelopmental disorders characterized by social and communication
deficits, stereotyped behaviors, cognitive dysfunction, and deficits in adaptive behaviors.
The pathogenesis underlying these disorders remains unknown, and thus no
pharmacologic or genetic therapies are currently available. Recent progress in the field
has shown that haploinsufficiency of the AT-rich interactive domain-containing 1B
(ARID1B) gene is a genetic cause of ASD and ID. Our lab recently developed an Arid1b
knockout mouse model to better study its role in the pathogenesis of these disorders.
One theory regarding the cause of neurodevelopmental disorders is disruption of the
excitatory/inhibitory balance in the brain. We previously showed that interneuron deficits
lead to an excitatory/inhibitory imbalance in Arid1b knockout mice, playing a significant
role in the observed behavioral phenotypes. Interneurons are highly heterogenous cell
types in the brain; however, little is known regarding how the different subtypes
modulate various behaviors. In chapter 2, we dissect the individual roles of the two most
populous interneurons in the cerebral cortex, parvalbumin and somatostatin subtypes, in
ASD/ID behaviors seen with ARID1B haploinsufficiency. We show that parvalbumin
interneurons affect social and emotional behaviors, while somatostatin interneurons
primarily affect stereotyped behaviors and cognitive function.
In addition to interneuron deficits, several studies have also implicated altered
neurite outgrowth of cortical projection neurons in ASD and ID. Furthermore, deficits in
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neurotrophic signaling, a master regulator of neurite outgrowth, is also frequently
observed. In chapter 3, we examine a potential role of ARID1B in regulating neurite
development of excitatory neurons during corticogenesis. We show that loss of the
Arid1b gene leads to disrupted neurite outgrowth and altered development of the corpus
callosum. Additionally, we suggest a likely role of ARID1B in the BDNF neurotrophic
signaling pathway. Together, these studies provide insight into possible roles of ARID1B
during neurogenesis, shedding further insight into the pathogenesis of ASD and ID.
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CHAPTER1: INTRODUCTION
1.1 Cortical neuron development in rodents
1.1.1 Development of inhibitory interneurons
Interneurons, which release the inhibitory neurotransmitter gamma-aminobutyric
acid (GABA), make up approximately 10-15% of all cortical neurons in rodents
(Tremblay et al., 2016). The development of inhibitory interneurons begins with
differentiation of interneuron progenitors into immature interneurons (occurs from ~E9.5E18.5), followed by migration of interneurons to their destination within the cortex (~E13P6), and finally maturation and integration into the local cortical circuitry (~P4-3rd
postnatal week) (Lim et al., 2018). Interneuron progenitor cells reside in the embryonic
ganglionic eminence (GE) within the telencephalon, where they give rise to postmitotic
interneurons. Newly differentiated postmitotic interneurons undergo two phases of
migration: a long tangential migration to reach the cortical plate (~E13-P2), followed by
radial migration as they disperse throughout the developing cortex (~E17-P6) (Lim et al.,
2018). The majority of cortical interneurons originate from the medial ganglionic
eminence (MGE), caudal ganglionic eminence (CGE), and preoptic area (POA), and
interneurons from these regions use essentially the same cellular mechanisms as they
migrate to the cortex (Cossart, 2011; Wonders and Anderson, 2006). Tangential
migration toward the cortex involves an interplay between chemorepulsive factors in the
GE, such as semaphorins 3A and 3F, and chemoattractive cues at the cortical plate,
such as neuroligin 1 (Lim et al., 2018). Additionally, actin and microtubule dynamics
appear to play a mechanistic role in the migration process of interneurons. Ka et al.
show that microtubule actin crosslinking factor 1 (MACF1) regulates GABAergic
interneuron migration and positioning during mouse cortical development (Ka et al.,
2017). Conditional deletion of Macf1 in interneuron progenitors led to fewer cortical
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interneurons, abnormal positioning, and altered speed and mode of migration due to
decreased microtubule stability (Ka et al., 2017). During tangential migration,
interneurons gradually begin to acquire their biochemical markers that contribute to the
diversity of subtypes. However, other differentiating characteristics, such as morphology,
connections, and physiological properties, do not appear until much later postnatal
developmental stages (Cossart, 2011; Lim et al., 2018). Upon reaching the cortical plate,
interneurons switch from the tangential mode to the radial mode of migration. Studies
indicate that this switch is linked to the interneuron’s loss of responsiveness to the
chemokine Cxcl12 (Lim et al., 2018). Additionally, pyramidal cells in the cortex express
neuregulin 3, facilitating the attraction of interneurons into the laminar dimension of the
cortex (Miyoshi and Fishell, 2011). Other studies recapitulate the suggestion that the
laminar distribution of interneurons is highly dependent on the activity of pyramidal cells.
For example, interneurons do not begin to acquire their position within their cortical layer
until after corresponding pyramidal cells have occupied the same layer (Hevner et al.,
2004; Pla et al., 2006). Further, disrupting the proper positioning of pyramidal cells
results in altered laminar distribution of interneurons (Lodato et al., 2011; Pla et al.,
2006). Eventually, upregulation of the potassium/chloride exchanger KCC2 in
interneurons reduces the frequency of intracellular calcium transients and inhibits the
motility of interneurons (Bortone and Polleux, 2009). This leads to the termination of
radial interneuron migration.
Following migration to their final destination in the cortex, interneurons begin to
integrate into the functional cortical circuitry. Similar to other neurons in the nervous
system, a surplus of GABAergic interneurons is generated during development. About
30% of interneurons are eliminated through apoptosis before the second postnatal week
(Lim et al., 2018). Xu et al. show that integration into cortical circuits influences their
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probability of survival, and interneurons that do not receive excitatory inputs during the
first week of postnatal development are likely to undergo apoptosis (Xu et al., 2004).
Interneurons that do survive function in three main circuit motifs in the cortex, including
feedforward inhibition, feedback inhibition, and disinhibition (Kepecs and Fishell, 2014;
Qu et al., 2016; Tremblay et al., 2016). While all interneuron types likely contribute to
these circuit motifs to some extent, it appears that specific subtypes exhibit more
prominent roles in one motif over another. For example, optogenetic techniques show
that VIP interneurons in the cortex have a primary role in disinhibition of SST
interneurons, ultimately inhibiting SST input to pyramidal cells (Pi et al., 2013). Within
these various circuit motifs, GABAergic interneurons play important roles in controlling
the timing of pyramidal cell firing, synchronizing network activity, and generating cortical
rhythms by modulating the level of excitation (Rudy et al., 2011). While the majority of
interneurons target nearby cells and control local network activity, some cortical
GABAergic neurons also project to other brain regions. Long-range cortical interneurons
have been found to connect to other cortical areas, the hippocampus, amygdala, and
basal ganglia (Caputi et al., 2013; Lee et al., 2014). In addition to providing inhibitory
input, another major function of GABAergic interneurons is to establish transient
microcircuits during early postnatal development that modulate the maturation of
network oscillations associated with behavioral and cognitive functions (Cossart, 2011;
Le Magueresse and Monyer, 2013). Furthermore, in addition to releasing GABA,
interneurons are also a source of neuropeptides such as somatostatin, vasoactive
intestinal peptide, and neuropeptide Y, which have significant neuromodulatory effects
(Rudy et al., 2011; Tremblay et al., 2016). These many facets of interneuron involvement
are indicative of their importance in overall brain development and function.
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1.1.2 Interneuron diversity and heterogeneity
Cortical interneurons are a highly heterogenous group of cells that exhibit diverse
morphologies, molecular markers, connectivity patterns, and physiological properties
(Lim et al., 2018; Xu et al., 2004). This level of heterogeneity is obtained throughout
development as a result of the combinatorial selection of different transcription modules
(Harris et al., 2018; Paul et al., 2017). RNA sequencing studies have revealed a high
level of diversity in transcription factor (TF) expression among interneuron progenitors
(Mayer et al., 2018). This TF heterogeneity is conserved throughout the maturation
trajectory as progenitors differentiate into diverse subtypes of interneurons. Furthermore,
mutations in various TFs at different developmental time points leads to several deficits
in interneuron fate, including abnormal migration, positioning, marker expression, and
synaptic activity, indicating functional importance of the diverse TF expression (Wonders
and Anderson, 2006).
Cortical interneurons are organized into several major classes based on their
transcriptional similarities and specific marker expression, which are even further broken
down based on other factors such as morphology, intrinsic physical properties, and
cortical distribution. Previous studies indicate that interneurons expressing the calciumbinding protein parvalbumin (PV), the neuropeptide somatostatin (SST), and the
ionotropic serotonin receptor 5HT3a (5HT3aR) account for almost all of the interneurons
in the rodent cortex (Rudy et al., 2011). The largest class of interneurons is
characterized by PV expression and exhibit fast-spiking firing properties (Kepecs and
Fishell, 2014; Lim et al., 2018; Rudy et al., 2011; Tremblay et al., 2016). Three major
subclasses of PV interneurons, each exhibiting distinct morphologies, are chandelier
cells, basket cells, and translaminar interneurons. Chandelier cells synapse onto
pyramidal cells at the initial segment of the axon, and they are primarily located between
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cortical layers 1 and 6 and in layer 6 (Somogyi et al., 1982; Taniguchi et al., 2013).
Basket cells, the most abundant interneuron type in the cortex, synapse onto the soma
and proximal dendrites of pyramidal cells and other interneurons, and they are
distributed throughout cortical layers 2 to 6 (Hu et al., 2014; Klausberger and Somogyi,
2008). Translaminar interneurons are a rare category of neurons, primarily in layers 5
and 6, that target pyramidal cells throughout most cortical layers (Bortone et al., 2014).
The second largest class of cortical interneurons are characterized by SST expression
(Kepecs and Fishell, 2014; Lim et al., 2018; Rudy et al., 2011; Tremblay et al., 2016).
Two major types of SST interneurons, Martinotti and non-Martinotti cells, preferentially
synapse onto dendrites of other interneurons and pyramidal cells (Klausberger and
Somogyi, 2008). Most Martinotti cells reside in layer 5 of the cortex, and they exhibit
fairly diverse firing patterns (Hilscher et al., 2017; Silberberg and Markram, 2007), while
non-Martinotti cells are distributed throughout layers 2 to 6 and exhibit a higher firing
frequency than Martinotti cells (Nigro et al., 2018). The cortex also contains GABAergic
interneurons expressing SST that exhibit long-range projections. These cells are
primarily found in deep cortical layers, project to other regions in the cortex, and
frequently co-express nitric oxide synthase (NOS) and neuropeptide Y (NPY) (He et al.,
2016). The third class of cortical interneurons expressing 5HT3aR is highly
heterogenous, and the most abundant of these types are those expressing vasoactive
intestinal peptide (VIP) (Kepecs and Fishell, 2014; Lim et al., 2018; Rudy et al., 2011;
Tremblay et al., 2016). Bipolar VIP interneurons in layers 2 and 3 of the cortex exhibit
continuous adapting firing properties and co-express the calcium-binding protein
calretinin (CR) (Pronneke et al., 2015). Less is known about multipolar VIP interneurons.
5HT3aR interneurons that do not express VIP are abundant in cortical layer 1, have late
spiking firing properties, and frequently co-express reelin and NPY (Lee et al., 2010;
Tasic et al., 2016). Table 1.1 summarizes the heterogeneity of interneuron subtypes.
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The highly heterogenous nature of interneurons suggest that there is marked functional
diversity among them. Current and future studies will further elucidate the various
functional differences between subtypes.
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Main markers

Parvalbumin (PV)

Somatostatin (SST)

5HT3aR
VIP

Non-VIP

Morphological
types

Basket

Chandelier

Martinotti

non-Martinotti

Bipolar and multipolar

Single bouquet and
neurogliaform

Targeting bias

Soma and proximal dendrites

Axon initial segment

Dendrites

Dendrites

Interneurons

Interneurons

Anatomical
properties

• Most common type
• Present in L2-L6
• Most prominent in L4 & L5
• Multipolar dendritic arbor
• Mostly targets pyramidal
cells and other PV cells
• Axonal arbor largely
dispersed

• Mainly found in L2 &
L6
• Multipolar dendritic
arbor
• Only targets pyramidal
cells
• Local axonal arbor

• Found in L2-L6
• Abundant in L5
• Multipolar & bitufted
dendritic arbor
• Local axon arbor
• Little connection with
other SST cells

• Found in L4 & L5
• Multipolar or bitufted
dendritic arbor
• Axon arbors in L4 & L5
• Preferentially targets
PV cells

• Enriched in L2/3
• Mostly bipolar
• Intracolumnar
dendritic and
axonal arbors

Biophysical
properties

• Fast spiking firing
• Low input resistance
• Brief action potential
• Little or no spike frequency
adaptation

Fast spiking firing, slightly
slower than typical FS
basket cells

• Low threshold
spiking
• High input resistance
• Spike frequency
adaptation
• Low max frequency

• Quasi fast spiking
firing
• Low input resistance
• Fast action potential
• Spike frequency
adaptation
• High max frequency

• Irregular spiking
and bursting firing
patterns
• High input
resistance
• Mostly adapting

• Low spiking firing
pattern
• High input resistance
• Electrically coupled
with other
interneuron types

Synaptic
properties

Fast, strong, and depressing
excitatory inputs and inhibitory
outputs

Depolarizing postsynaptic
effect

Facilitating excitatory inputs

Preferentially contact
SST interneurons

Activate GABAB
receptor, synaptic
fatigue

Other markers

Tac1

None

CR, NOS, Reelin, NPY

CR

Reelin, NOS, NPY

• Found in L1-L6
• Abundant in L1
• Multipolar dendritic
arbor
• Translaminar axon

Table 1.1 Interneuron diversity
Nearly all the interneurons in neocortex express one of the main three non-overlapping markers: parvalbumin
(PV, blue), somatostatin (SST, yellow), and the ionotropic serotonin receptor 5HT3a (5HT3aR, green). Further
subdivisions within each molecular group are revealed by morphological features, cellular and subcellular
targeting biases, and expression of other markers, as well as some known anatomical, electrophysiological, and
synaptic properties.
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Both spatial and temporal factors, regulated by a network of transcription factors,
contribute to the origin of interneuron diversity. The major classes of interneurons are
derived from distinct regions. The MGE and POA give rise to both PV and SST
interneuron types, and the CGE gives rise to the class of 5HT3aR interneurons (Butt et
al., 2017; Lim et al., 2018). Further, PV interneurons are born throughout the majority of
the embryonic time window for neurogenesis (E9.5~E18.5), SST interneurons are born
during the first half of the neurogenic period (E9.5~E14.5), and 5HT3aR subtypes are
born at the latter half of the neurogenic period (E12.5~E18.5) (Butt et al., 2017; Kepecs
and Fishell, 2014; Wonders and Anderson, 2006). Figure 1.1 illustrates the
spatiotemporal origins of interneuron diversity and the underlying transcription factors
involved.
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a.

CGE

Pax6
Prox1
Nr2f2
Sp8

MGE

Nkx6-2
Nr2f2
Otx2
Etv1
Lhx6/8
Sox6

Dlx1/2
Dlx5/6
Nkx2-1

5HT3aR bipolar cells
5HT3aR single bouquet cells

PV chandelier cells
PV basket cells
PV translaminar cells
SST Martinotti cells
SST non-Martinotti cells
SST long-projecting cells

Dbx1
Nkx6-2
Hmx3

POA

PV
SST
5HT3aR

Interneuron type

b.

~E9.5
~E18.5
Interneuron birth date

Figure 1.1 Spatiotemporal origins of interneurons
The three main classes of cortical interneurons are derived from distinct regions at specific
time points, regulated by a network of transcription factors. a. Spatial origins of interneuron
subtypes regulated by a network of transcription factors. b. Temporal origins of interneuron
subtypes.
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1.1.3 Development of excitatory projection neurons
Excitatory projection neurons, which release the neurotransmitter glutamate,
make up approximately 85-90% of neurons in the rodent cortex (Tremblay et al., 2016).
These glutamatergic neurons may project to other cortical areas as well as subcortical
targets, and are crucial for transmitting information across brain regions. Cortical
development begins at approximately E10, after closure of the neural tube, and
continues until around postnatal week three (Azzarelli et al., 2014; Barnes and Polleux,
2009). The first stage of development involves maintaining a pool of embryonic stem
cells (ESCs) and neural progenitor cells (NPs), followed by differentiation of NPs into
immature neurons. One type of progenitor cell, neuroepithelial cells (NEs), line the
lateral ventricles and self-renew to expand the progenitor pool (Azzarelli et al., 2014;
Kast and Levitt, 2019). These cells then convert into another type of progenitor cell,
radial glial cells (RGs), which are bipolar cells whose cell body resides in the ventricular
zone (VZ). These neural precursors can divide symmetrically to self-renew, or
asymmetrically to differentiate into immature cortical projection neurons. Initially, RGs
generate neurons directly (direct neurogenesis), but begin to produce a second
population of neural precursors called intermediate progenitors (IPs) around E13.5.
These IPs exhibit a multipolar morphology and migrate along the glial process of RGs to
the subventricular zone (SVZ), where they undergo additional rounds of self-renewal to
increase the yield of cortical neurons derived from a single RG, followed by asymmetric
division to generate immature neurons (indirect neurogenesis) (Barnes and Polleux,
2009). Neural progenitors continue to actively proliferate and generate neurons between
E10 and E17 (Azzarelli et al., 2014). The balance between proliferation and
differentiation of the different neural progenitors is tightly controlled by cytoskeletal
remodeling. Multiple signaling networks regulate these cytoskeletal dynamics. Activity of
several small Rho GTPases, including RhoA, Rac1, and Cdc42, initiate downstream
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signaling to regulate actin and microtubule (MT) components of the cytoskeleton during
proliferation and differentiation (Azzarelli et al., 2014; Namba et al., 2015). Additionally,
mammalian target of rapamycin (mTOR) signaling regulates the cell cycle progression of
neural progenitors and disrupts progenitor self-renewal by altering cytoskeletal dynamics
(Ka et al., 2014a). Mice with loss of mTOR in neural progenitors present with reduced
brain size and cortical thickness as well as suppressed differentiation. Ka et al. also
showed that glycogen synthase kinase 3 (GSK3), a master regulator of the switch from
self-renewal to neurogenesis in neural progenitor cells, controls the activity of mTOR in
progenitors (Ka et al., 2014a). GSK3 exhibits a baseline level of activity in resting cells,
and inactivation promotes progenitor proliferation while further activation promotes
neuronal differentiation (Hur and Zhou, 2010; Jung et al., 2015). Downstream signaling
of GSK3 controls neurogenesis by altering MT organization and modulating pathways
regulating progenitor proliferation, such as Wnt, Shh, Fgf, and Notch signaling (Hur and
Zhou, 2010; Kim et al., 2009). MACF1, a MT plus-end binding protein, also regulates the
dynamics of MTs during neurogenesis (Moffat et al., 2017). Loss of MACF1 and
abnormal stabilization of MTs can suppress cell division.
Following differentiation, an immature neuron then enters the next stage of
development, which is migration to its final destination within the cortex. During
migration, which occurs from approximately E11 to E18, newborn neurons detach from
the ventricular surface and migrate radially toward the pial surface of the cortex while
using RG fibers as a scaffold (Azzarelli et al., 2014). The cortex is generated in an
inside-out manner, meaning that neurons born earlier will occupy the deepest layers of
the future six-layered neocortex, whereas later born neurons by-pass the early neurons
and settle in more superficial layers (Azzarelli et al., 2014; Kast and Levitt, 2019).
Immature neurons first acquire a multipolar shape at early stages of migration, and then
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transition to a bipolar morphology with a leading and a trailing process (Lewis et al.,
2013). The leading process directed toward the pial surface will eventually become the
apical dendrite, and the trailing process will become the nascent axon (Azzarelli et al.,
2014; Barnes and Polleux, 2009). Cytoskeletal dynamics play an essential role in the
multipolar-to-bipolar transition and migration processes. Dynamic organization of actin
and microtubules controls the interaction between the migrating neuron and the glial
process, and disruption results in deficits in migration (Azzarelli et al., 2014; Barnes and
Polleux, 2009). Deletion of mTOR alters downstream cytoskeletal dynamics and results
in abnormal migration and neuron positioning (Ka et al., 2014a). Additionally, loss of
MACF1 disrupts the leading process morphogenesis and MT dynamics during radial
migration, leading to similar deficits in migration and positioning (Ka et al., 2014b; Moffat
et al., 2017). Upon reaching their location in the cortex, neurons continue to mature as
they develop complex axon and dendrite networks, ultimately constructing the intricate
circuitry of the brain. The trailing process becomes the nascent axon as it extends
rapidly and is guided to its target area within the brain, which lasts until around postnatal
day 7 (P7) (Lewis et al., 2013). During the second and third postnatal week (P8-P21),
further axonal branching and dendritic spine formation occurs during the formation of
presynaptic contacts with postsynaptic targets (Lewis et al., 2013). Apoptosis is an
essential step during the stages of axon growth, branching, and synaptogenesis.
Neuronal apoptosis in the cortex occurs during the first 30 postnatal days in order to
refine neuronal innervation and network formation (Azzarelli et al., 2014). This accounts
for approximately a 30% loss of neurons in the cortex from birth to adulthood. Cortical
projection neurons can be divided into three broad classes (Kast and Levitt, 2019). The
first is corticothalamic neurons, which are located primarily in layer 6 and project to the
thalamus. The second is the pyramidal tract neurons that are exclusively located in layer
5 and have axons that extend toward the brain stem and spinal cord. The third class is
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the intratelencephalic neurons within layers 2-6 that extend axons toward targets in the
contralateral and ipsilateral cortex, striatum, nucleus accumbens, amygdala, and other
structures. Fate decisions of which class projection neurons will belong to occurs shortly
after cell division, during the early stages of migration (Kast and Levitt, 2019). Local
microcircuitry connections within the cortex are established around the first week, while
long-range projections develop over the first two-three postnatal weeks (Kast and Levitt,
2019). The stages of excitatory projection neuron development in the cortex are
illustrated in Figure 1.2.

14

Basal

L1

MZ
7
5

L2-3

6

CP
L4
4
3

IZ

L5
SVZ

2
1

L6

VZ
Apical
E10

P21

Figure 1.2 Excitatory neuron development in the rodent cortex
The following are the steps of excitatory neuron development in vivo: 1) Radial glial neural
progenitor cells undergo symmetric cell division to self-renew. 2) Asymmetric division of a radial
glial cell generates an immature projection neuron. 3) The immature neuron detaches from the
ventricular surface and begins to migrate radially, acquiring a multipolar morphology. 4) The
nascent neuron becomes bipolar, extending a leading process toward the pial surface and trailing
process in the opposite direction as it continues migrating along the glial process. 5) During
migration, the trailing process becomes the axon and begins to extend and the neuron detaches
from the glial process as the leading process reaches the marginal zone. 6) The leading process
gives rise to the apical dendrite and initiates branching in the marginal zone as the nascent axon
continues to extend. 7) The neuron matures as the axon continues to extend to its final location,
basal dendrites develop at the soma, and dendritic spines begin to form.
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1.2 Chromatin remodeling in neural development
Proper brain development is regulated by highly orchestrated processes. Master
transcription factors must activate or repress specific downstream genes at the right
place and right time in a highly coordinated fashion. Genetic material is highly
compacted and packaged around histones within the nucleus, so only certain genes are
accessible to transcription factors at a given time (Kornberg, 1974). The role of
chromatin modifiers is to create dynamic changes in the structure of chromatin, which
allows TF access to regulate various genes both spatially and temporally. There are two
main epigenetic mechanisms utilized by chromatin modifiers to regulate the state of
chromatin. The first is covalent modification of histone tails, such as acetylation, which
regulates the accessibility of DNA to regulatory mechanisms (Mehler, 2008; Ronan et
al., 2013). The second is ATP-dependent remodeling of DNA-nucleosome topology,
which physically alters the state of chromatin by moving nucleosomes in relation to DNA
or exchanging nucleosomes into and out of DNA (Ronan et al., 2013; Sim et al., 2015).
Both histone modifiers and physical chromatin remodelers work in concert to regulate
chromatin structure and gene expression. Several chromatin modifiers and remodelers
play important roles in the major events during neural development. BRG1/BRM
associated factor (BAF) and chromodomain helicase DNA binding protein 8 (CHD8),
which are two ATP-dependent chromatin remodelers, histone deacetylase 4 (HDAC4),
and enhancer of zeste homolog 2 (EZH2), which is a histone methyltransferase, all have
common pathways in regulating neural development, from proliferation and
differentiation to synaptogenesis (Day and Sweatt, 2011; Mehler, 2008; Ronan et al.,
2013).
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1.2.1 BAF chromatin remodeling complex
One chromatin remodeler, the BAF chromatin remodeling complex, is highly
expressed throughout all stages of mammalian brain development (Ho and Crabtree,
2010; Wang et al., 1996). Since its original discovery in yeast, the evolution of the
mammalian BAF complex has involved the addition of new subunits and the use of
combinatorial subunit assembly to develop different forms of the complex for tissuespecific expression. The primary roles of the additional subunits gained in mammalian
complexes appear to be in cell cycle control and regulation of neurodevelopment (Son
and Crabtree, 2014). Specific BAF complexes are expressed in embryonic stem cells,
neural progenitor cells, and mature neurons, and are referred to as esBAF, npBAF, and
nBAF, respectively. All BAF complexes are composed of 12-15 subunits, including a
core ATPase subunit (BRG1 or BRM). The ATPase subunits also contain a
bromodomain, which binds to acetylated lysine residues in histone N-terminal tails. It is
suggested that this helps with stabilizing the association between the complex and
chromatin (Ronan et al., 2013). The complex also contains a subunit with a DNA-binding
domain, Arid1a or Arid1b, that targets the complex to DNA (Wang et al., 2004). Other
subunits in the complex have been shown to interact with DNA regulatory proteins.
These subunits bind to transcription activators or repressors, which help target the
complex to promoters. Studies have shown that the roles of these subunits have
redundant functions to Arid1a/b, and their primary role is to support the function of
Arid1a/b (Martens and Winston, 2003). Without these other subunits present, the BAF
complex is still successfully targeted to promoter sites. Image reconstruction techniques
show that the subunits come together and form a groove within the center of the
complex where nucleosome binding and remodeling occurs (Tang et al., 2010).
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The BAF complex uses energy from ATP hydrolysis to remodel chromosome
structure by altering DNA-histone contacts within a nucleosome (Celen et al., 2017;
Martens and Winston, 2003). There are two proposed models regarding the mechanism
of chromatin remodeling by the BAF complex: nucleosome sliding and nucleosome
ejection and insertion (Peterson and Workman, 2000; Tang et al., 2010; Wilson and
Roberts, 2011). The nucleosome sliding mechanism includes binding of the complex to
nucleosomal DNA, disruption of the histone-DNA contacts by ATP hydrolysis,
translocation of DNA though the ATPase subunit, and finally the formation of a DNA loop
that then gets propagated around the nucleosome to generate sites accessible to DNA
binding factors. The complex then resets its original position to prepare for a new cycle
of remodeling. The mechanism of how nucleosome ejection and insertion occurs is not
as well known. It has been suggested that after positioning of the bound nucleosome,
histone ejection, with assistance of histone chaperones, may occur at adjacent
nucleosomes rather than the nucleosome directly bound to the complex (Peterson and
Workman, 2000). The BAF complex acts as both an activator and repressor of gene
transcription, either by positioning the nucleosomes away from DNA binding sites to
facilitate interaction of TFs, or by moving nucleosomes over binding sites to prevent TF
interaction (Lopez and Wood, 2015). The activity of the chromatin remodeler is not
directly instructive, but it instead establishes either permissive or restrictive
environments for gene expression. This dynamic interplay between gene activation and
repression is crucial during the intricate stages of neural development. For example, as
proliferating stem cells begin to differentiate into neural progenitors, proliferationassociated genes must become more suppressed while cell lineage specific genes must
begin to be activated (Wilson and Roberts, 2011).
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As cells mature in the developing brain from embryonic stem cells, to neural
progenitor cells, to mature neurons, they undergo global chromatin changes regulated
by the expression of tissue-specific BAF complexes: esBAF, npBAF, and nBAF,
respectively. This change in BAF subtype requires essential switches in subunit
composition in order to perform the functions necessary for different cell types. Several
studies have illustrated roles of specific BAF subunits in various stages in neural
development. The esBAF complex has an important role in maintaining the self-renewal
and pluripotency of mouse embryonic stem cells (Ho and Crabtree, 2010). The BRG1,
BAF155, and BAF170 subunits are essential in regulating these processes. Loss of
function in any of these components leads to loss of proliferative activity and
pluripotency (Son and Crabtree, 2014). To differentiate into cells of different lineages,
pluripotent ESCs must suppress genes that potentiate a state of self-renewal. BAF155
and BAF57 subunits are essential to exit from this state (Ho and Crabtree, 2010; Ho et
al., 2009). As ESCs differentiate into NPs, esBAFs exclude the BAF60B subunit in
exchange for BAF60C to become npBAFs (Lessard et al., 2007). NPs are a focal point
for intricate regulation of brain development. They must downregulate the pluripotency
gene network while still retaining proliferative properties, and they must simultaneously
suppress the neuronal differentiation gene network. BRG1 and BAF155 subunits both
participate in progenitor self-renewal in addition to npBAF-specific subunits BAF53A,
BAF45A, and BAF60C (Son and Crabtree, 2014). Additionally, BAF170 interacts with
Pax6 to regulate the specification of layer identity, which contributes to the regulation of
cortex size and composition (Tuoc et al., 2013). Downstream target genes of Pax6
regulate the generation of intermediate progenitors and late cortical progenitors during
early stages of development. Loss of BAF170 promotes indirect neurogenesis by
increasing the pool of IPs, resulting in increased cortical size and thickness (Tuoc et al.,
2013). As NPs leave their stem-cell niche and exit mitosis, the npBAF complex
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exchanges BAF45A and BAF53A subunits for BAF45B and BAF53B to become the
nBAF complex (Lessard et al., 2007). The nBAF complex interacts with the Ca2+responsive protein CREST to regulate downstream genes associated with activitydependent dendrite and axon outgrowth, contributing to proper circuitry formation during
late stage development (Lopez and Wood, 2015; Wu et al., 2007). nBAF subunit
BAF53B also regulates transcription and cytoskeletal dynamics downstream of activitytriggered Ca2+ signaling, affecting the formation of long-term memory (Lopez and Wood,
2015; Son and Crabtree, 2014). Mice with mutations in BAF53B have deficits in spine
morphology, synaptic plasticity, cytoskeletal dynamics, and long-term memory (VogelCiernia et al., 2013). A triple negative circuit underlies the mechanism of the switch
between BAF complex types (Lessard et al., 2007; Son and Crabtree, 2014). In one cell
type, miRNAs bind to the gene transcript of the subunit to be suppressed, resulting in
inhibition of translation and subsequent mRNA degradation. The transcriptional
repressor REST will repress these miRNAs in the other cell type to maintain expression
of the subunit. This mechanism is present in each cell type containing BAFs, so precise
control of subunit expression is maintained throughout the stages of neural development
(Lessard et al., 2007).
Chromatin remodeling by BAF complexes work in cooperation with covalent
chromatin modifiers. The complex has a global effect on epigenetic events, influencing
acetylation (active marks) and methylation (repressive marks). Loss of function in the
various BAF complexes results in reduced acetylation events and increased methylation
events, accompanied by decreased downstream expression of neurodevelopmentassociated genes (Narayanan et al., 2015). Therefore, the presence of the BAF
complexes provides a crucial balance between active and repressive activity of
chromatin during development. In addition, the BAF complexes work with master
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transcription factors to maintain proper transcription activity during neurodevelopment.
For example, the esBAF complex regulates expression of genes also targeted by TFs
known to control stem cell renewal, including OCT4, SOX2, STAT3, and SMAD1 (Ho
and Crabtree, 2010). Further, the npBAF complex converges on the same genes of TFs
that target pathways involved in neurogenesis, including NOTCH and SHH. The above
studies all underscore the important and diverse roles of the BAF complexes during
several stages of neurodevelopment.
1.2.2 Role of Arid1b subunit
AT-rich interacting domain-containing protein 1B (ARID1B), one subunit of BAF
chromatin remodeling complexes, is a 240 kDa protein that facilitates targeting of the
complex to chromatin (Celen et al., 2017). There are three known domains of the Arid1b
gene. A DNA-binding domain interacts with AT-rich DNA of its target genes and a
protein-binding domain interacts with other proteins, including BRG1 and BRM subunits
(Sim et al., 2015). A third domain contains a BC box domain, which associates with
three additional proteins, Elongin C, Cullin 2, and Roc1, to assemble an E3 ubiquitin
ligase (Li et al., 2010; Zheng and Shabek, 2017). This functions to target histone H2B at
lysine 120 for monoubiquitination, suggesting a role of Arid1b in the cross talk of histone
modifications. Arid1b is expressed throughout the cortical layers and hippocampus of the
rodent brain during embryonic and postnatal development and into adulthood (Celen et
al., 2017; Ka et al., 2016a). Its expression has also been verified throughout other
regions of the brain, including the dorsal and ventral telencephalon and cerebellum.
Arid1b is localized within the nucleus and is specific to ESCs and cells in the neuronal
lineage, as expression is absent in glial cells (Ka et al., 2016a). The Arid1b subunit of
the BAF complex is crucial for cell cycle regulation and differentiation during mammalian
brain development. Deficiency of Arid1b reduces the self-renewal capacity of ESCs (Sim
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et al., 2015; Yan et al., 2008). In addition, Arid1b is essential for ESCs to maintain
pluripotency properties. Inactivation of Arid1b results in ESCs that exhibit characteristics
of differentiated cells, such as reduced expression of pluripotency-associated genes and
elevated expression of differentiation-associated genes (Yan et al., 2008).
1.2.3 Chromatin remodeling deficits in neurodevelopmental disorders
Deficits in epigenetic modifications have been implicated in neurodevelopmental
disorders. Considerable study has been done on the roles of histone acetylation and
DNA methylation in disease progression. Mutations in the histone deacetylase HDAC4
and methyltransferase EZH2 have both been associated with ASD and ID (Gibson et al.,
2012; Williams et al., 2010). More recently, the role of nucleosome remodelers in these
disorders has received considerable attention. Mice with loss of function mutations in the
ATPase chromatin remodeler CHD8 exhibit autism-related phenotypes and cognitive
dysfunction (O'Roak et al., 2012a). In addition, mutations in a single allele of multiple
BAF complex subunits have been discovered in several human patients with ASD and
ID. Missense mutations in Arid1a, BRM, BRG1, BAF47, BAF155, BAF170, and BAF180
have all been identified (Neale et al., 2012; O'Roak et al., 2012b; Santen et al., 2012b;
Van Houdt et al., 2012). Loss of function mutations in the Arid1b subunit are the most
frequently occurring ASD/ID-associated mutations of the BAF complex (Halgren et al.,
2012; Hoyer et al., 2012; Santen et al., 2012a; Tsurusaki et al., 2012). The following
section discussions these various Arid1b mutations and their role in neurodevelopmental
disorders.
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1.3 Haploinsufficiency of ARID1B
1.3.1 Human ARID1B mutations
Recent studies have shown that ARID1B mutations are prevalent in
neurodevelopmental disorders, including ASD, ID, and Coffin-Siris syndrome (CSS).
ASD, which is characterized by severe social and communication deficits as well as
stereotyped behaviors, affects approximately 1 in 68 individuals (Walsh et al., 2011). ID
is seen in about 75% of ASD patients, and affects approximately 1-3% of the overall
population. Individuals with ID experience significant limitations in cognitive function and
adaptive behavior (Ellison et al., 2013). Next generation sequencing from eight ID
patients all show de novo translocations or deletions that result in a truncated copy of
the ARID1B gene (Halgren et al., 2012). Of these, five patients exhibit phenotypes
consistent with ASD and four patients also have abnormalities of the corpus callosum.
Mutational analysis in another 887 patients with unexplained ID showed nine patients
with de novo nonsense or frameshift mutations resulting in truncated ARID1B (Hoyer et
al., 2012). CSS is a severe form of intellectual disability, characterized by developmental
delay, severe speech impairment, coarse facial features, hypoplastic or absent fifth
fingernail or toenail, and agenesis of the corpus callosum (Tsurusaki et al., 2012).
Exome sequencing of 23 individuals diagnosed with CSS revealed 6 patients with de
novo mutations in one copy of ARID1B (Tsurusaki et al., 2012). Whole-exome
sequencing done by Santen et al. on three patients with CSS also revealed de novo
truncating mutations of ARID1B in all individuals (Santen et al., 2012a). Additionally,
copy-number variation analysis in 2,000 individuals affected with ID showed that three
subjects with ARID1B gene deletions also exhibited phenotypes overlapping with CSS
(Santen et al., 2012a).
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Most of the discussed mutations are genetically dominant, and they occur in the
DNA-binding domain of the gene, affecting the ability of the protein to target the BAF
complex to chromatin (Sim et al., 2015). Together, these studies reveal a number of de
novo mutations resulting in loss of function of one copy of the ARID1B gene. These
results strongly suggest that haploinsufficiency of ARID1B is a genetic cause of ASD
and ID, contributing to the evidence that chromatin remodelers play crucial roles during
neurodevelopment. Interestingly, Santen et al. discuss that several mutations in ARID1B
and other BAF subunits are also identified in a wide variety of tumors (Santen et al.,
2012b). Because the BAF complexes regulate many different cellular pathways involved
in cell proliferation, differentiation, and migration, it makes sense that inactivating
mutations may affect cancer development. Santen et al. suggest that there could be an
increased risk of malignancies in ASD/ID patients that carry mutations in these genes.
1.3.2 Knockdown of Arid1b and neuronal development
Maturation of neurons during the late stages of development involves intricately
regulated neurite outgrowth (Barnes and Polleux, 2009; Tsaneva-Atanasova et al.,
2009). The use of shRNA delivery into rodent brains via in utero electroporation revealed
that Arid1b plays a role in regulating the maturation of neurons during development.
Knockdown of Arid1b led to a reduction in dendritic outgrowth and arborization of
pyramidal neurons in the cortex and hippocampus (Ka et al., 2016a). This was
accompanied by a reduction in various neurite growth-associated genes, such as Stmn2,
Gprin1, and Gap43. In addition, Arid1b knockdown resulted in fewer dendritic
innervations into layer 1 of the cortex (Ka et al., 2016a). This is likely to alter synaptic
connectivity in the cortex, disrupting the balance between excitation and inhibition.
Following neurite development, mature neurons undergo synaptogenesis to form
connections and generate proper circuitry (Barnes and Polleux, 2009). After shRNA
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delivery, Arid1b-deficient neurons exhibit fewer dendritic spines, and of the spines
present, many of them exhibited immature, filopodia-like morphology (Ka et al., 2016a).
Abnormal spine development leads to impaired synaptic connectivity, likely contributing
to the pathology underlying ASD and ID.
1.3.3 Neural and behavioral deficits in Arid1b haploinsufficient mice
Three groups, including our own, have generated mouse models of Arid1b
haploinsufficiency that exhibit significant abnormalities in neural composition and
behavior (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017). Both Jung et al.
and Celen et al. generated heterozygous mice by removing exon 5 in one copy of the
gene, while Shibutani et al. removed exon 3. All methods resulted in frameshift
mutations and loss of function of the gene. Jung et al. observe abnormal cellular
composition in the cortex of Arid1b heterozygous mice. While there are no differences in
excitatory pyramidal neurons, oligodendrocytes, or astrocytes, GABAergic interneurons
are markedly reduced and abnormally positioned within the cortex (Jung et al., 2017).
Interneurons containing parvalbumin, somatostatin, calbindin, and calretinin are all
prominent in the makeup of cortical circuitry (Tremblay et al., 2016); however, only a
reduction in the PV subtype is observed (Jung et al., 2017). This is consistent with
previous studies linking a reduction in PV interneurons to ASD and related disorders
(Fukuda et al., 2005; Gogolla et al., 2009; Selby et al., 2007; Zikopoulos and Barbas,
2013). Previous studies have also indicated a disruption in inhibitory synaptic activity in
ASD (Fatemi et al., 2009; Jamain et al., 2008; Piton et al., 2013; Tabuchi et al., 2007).
Consistent with this, Arid1b heterozygous mice had fewer inhibitory synaptic puncta,
particularly vesicular inhibitory amino acid transporter- (VGAT) and glutamic acid
decarboxylase 2- (GAD2) positive puncta, as well as decreased miniature inhibitory
postsynaptic currents (mIPSCs) in the cortex, suggesting impaired inhibitory
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transmission (Jung et al., 2017). Deficits in interneuron number and activity together lead
to an excitatory/inhibitory imbalance in these Arid1b heterozygous mice. Celen et al. also
report various neuroanatomical abnormalities in Arid1b haploinsufficient mice, including
reduced corpus callosum volume, smaller dentate gyrus, and reduced cortical thickness,
likely resulting from decreased NP proliferation (Celen et al., 2017). These mice also
exhibit body growth impairments due to deficiencies in the growth hormone-releasing
hormone – growth hormone – insulin-like growth factor 1 (GHRH-GH-IGF1) axis.
Shibutani et al. report similar reduced body weight and hydrocephalus in Arid1b
heterozygous mice (Shibutani et al., 2017).
Heterozygous mice from all three groups also exhibit behavioral deficits
consistent with other ASD/ID mouse models and human patients. The findings between
the groups are primarily consistent, with a few exceptions. Social and communication
deficits and stereotyped behaviors are two hallmark features of ASD (Walsh et al.,
2011). All three groups report deficits in social behavior in the three-chamber test and/or
open field sociability test (Celen et al., 2017; Jung et al., 2017; Shibutani et al., 2017).
Celen et al. and Jung et al. also report stereotyped behaviors indicated by excessive
self-grooming, and Celen et al. report altered ultrasonic vocalizations, suggesting
communication deficits (Celen et al., 2017; Jung et al., 2017). Anxiety and depression
are common comorbidities seen with ASD (Fakhoury, 2015; Reid et al., 2011). The
elevated plus maze and open field test indicated increased anxiety in Arid1b
heterozygotes in all three groups (Celen et al., 2017; Jung et al., 2017; Shibutani et al.,
2017). Jung et al. also show increased depression-like behavior via the tail suspension
and forced swim tests (Jung et al., 2017). Interestingly, Shibutani et al. show
contradicting results in the forced swim test, suggesting reduced depression behavior
(Shibutani et al., 2017). Various factors, including animal handling and environmental
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stimuli, may affect contradictory results. ID is primarily characterized by deficits in
cognition (Daily et al., 2000; Ellison et al., 2013). Arid1b heterozygous mice present with
significant cognitive dysfunction. Jung et al. report deficits in learning and memory in the
novel object recognition test and Morris water maze (Jung et al., 2017). These mice also
present with motor learning deficits, indicated by the rotarod test. Shibutani et al. show
deficits in long-term fear memory, but novel object recognition and Morris water maze
assays were not performed (Shibutani et al., 2017). Celen at al. performed the Morris
water maze, but surprisingly, results indicated no dysfunction in spatial reference
memory (Celen et al., 2017). This is unusual given the prevalence of ARID1B mutations
identified in human ID patients (Halgren et al., 2012; Hoyer et al., 2012; Santen et al.,
2012a). Together, these results all suggest that Arid1b heterozygous mice recapitulate
the majority of behavioral phenotypes seen in ASD and ID, therefore providing a useful
tool moving forward to better understand the pathology underlying these disorders.
1.3.4 Downstream gene expression changes
As a chromatin remodeler, the primary function of the BAF complex is to regulate
gene expression in the brain (Son and Crabtree, 2014; Tang et al., 2010). Loss of the
Arid1b subunit, whose main role is to target the complex to its target genes, leads to
altered gene expression and contributes to the downstream neuronal effects of Arid1b
haploinsufficiency (Figure 1.3). Celen et al. report significant downregulation of 56 genes
and up-regulation of 79 genes in Arid1b heterozygous mice (Celen et al., 2017). The
majority of altered genes were associated with nervous system development and
psychological, behavioral, and developmental disorders. Approximately 10% of the
differentially regulated genes were among the highest-ranking autism risk genes
identified in the SFARI gene database (Basu et al., 2009; Celen et al., 2017).
Additionally, about 65% of these genes showed direct binding to the BAF complex
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(Celen et al., 2017). Using genome-wide RNA-Sequencing, Shibutani et al. showed that
the gene expression pattern of Arid1b heterozygote brains is similar to that in the brains
of autistic patients (Shibutani et al., 2017).
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Figure 1.3 Altered gene expression and neuronal effects of Arid1b
haploinsufficiency
Arid1b haploinsufficient mice exhibit altered expression of downstream genes,
leading to functional, anatomical, and behavioral deficits.
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Covalent modifications of histones, including acetylation and methylation, are
essential regulators of transcription (Day and Sweatt, 2011; Mehler, 2008). Jung et al.
report that Arid1b heterozygotes present with reduced acetylation of histone H3 at lysine
9 (H3K9ac) and tri-methylation of histone H3 at lysine 4 (H3K4me3), markers of
transcriptional activation, and increased tri-methylation of histone H3 at lysine 27
(H3K27me3), a marker of transcriptional repression (Jung et al., 2017). While this would
suggest that Arid1b haploinsufficiency suppresses activity of histone acetyltransferases
(HATs) or enhances activity of histone deacetylases (HDACs), no global differences in
HAT or HDAC activity were observed (Jung et al., 2017). However, levels of two HATs,
acetyl-CREB-binding protein (CBP) and P300/CBP-associated factor (PCAF), bound to
histone H3 were decreased in heterozygotes (Jung et al., 2017). These results indicate
that Arid1b may bridge the interaction between histone H3 and various HATs, supporting
evidence that chromatin remodelers and covalent modifiers work in cooperation with one
another to regulate gene expression.
Jung et al. also report a reduction in the parvalbumin (Pvalb) gene with Arid1b
haploinsufficiency, which is consistent with the observed decrease in PV positive
interneurons in the cortices of these mice (Jung et al., 2017). A reduction in the amount
of Arid1b bound to the Pvalb promoter and a decrease in H3K9ac at the promoter site is
also reported, likely resulting in decreased initiation of transcription of the gene (Jung et
al., 2017). Two additional genes associated with interneuron development, Gad1 and
Slc32a1, shared similar results: reduced gene expression and decreased binding of
Arid1b at the promoter sites (Jung et al., 2017). These results implicate the importance
of Arid1b in regulating interneuron-associated genes by interacting with gene promoters,
recruiting HATs, and facilitating chromatin remodeling for initiating transcription.
Furthermore, Arid1b haploinsufficiency was shown to reduce the expression of β-catenin
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and its localization to the nucleus, consequently reducing expression of several target
genes, including Cyclin D1, c-Myc, n-Myc, Creb, Lef1, and Ctnnb1 (Jung et al., 2017).
Wnt-β-catenin signaling plays a crucial role in regulating ventral progenitor proliferation
during neurodevelopment (Hur and Zhou, 2010; Vasileiou et al., 2015). Future studies
may reveal a role of Arid1b in the regulation of Wnt-β-catenin signaling and ventral
progenitor proliferation. A summary of ASD-associated genes with altered expression
levels in Arid1b heterozygotes can be found in Table 1.2.
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Gene

Description/Function

Gene

Description/Function

Grin2b

NMDA receptor subunit

Zbtb20

Transcription factor

Prickle1

Nuclear receptor

Nting1

Neurite outgrowth-promoting protein

Prickle2

Nuclear receptor

Robo1

Membrane protein involved in axon guidance and cell
migration

Homer1

Postsynaptic density scaffolding

Sspo

Neuronal aggregation modulator

Sox5

Transcription factor

Pvalb

Calcium-binding protein

Egr2

Transcription factor

Gad1

Enzyme for producing GABA neurotransmitter

Epha6

Receptor tyrosine kinase

Slc32a1

Vesicular inhibitory amine acid transporter

Lama1

Laminin alpha 1 subunit

Ctnnb1

Transduction of Wnt signaling

Rbfox1

Alternative splicing regulator

Ccnd1

Cell cycle regulation

Mkl2

Transcriptional coactivator

c-Myc/n-Myc

Transcription factors

Itga4

Integrin subunit

Creb

Transcription factor

Nbea

A-kinase anchor protein

Lef1

Activates T-cell receptor-alpha

Table 1.2 Select downregulated genes with Arid1b haploinsufficiency
Haploinsufficiency of Arid1b leads to reduced expression of several categories of genes,
including transcription factors, receptors and receptor subunits, regulators of cell cycle, and
components contributing to synaptic function.
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1.4 Autism spectrum disorder and intellectual disability
1.4.1 Genetic mouse models
To better elucidate the mechanisms underlying ASD, ID, and related
developmental disorders, several animal models have been developed. Rodents are an
ideal model for the study of neurodevelopmental and psychiatric disorders, as the
majority of these disorders have at least some component of genetic origins (Ayhan and
Konopka, 2019; Ellison et al., 2013; Krumm et al., 2014; Ropers and Wienker, 2015;
Srivastava and Schwartz, 2014) and there is significant homology between the human
and mouse genome (Eppig et al., 2015; Pennacchio, 2003). Additionally, rodents exhibit
an array of complex behaviors, which is helpful for studying disorders with significant
behavioral phenotypes. With the rise of novel tools for studying and manipulating
genetics, researches can better study the behavioral effects of genetic manipulation in
rodents (Heidenreich and Zhang, 2016).
ASD is characterized primarily by stereotyped behaviors and deficits in sociability
and communication (Fakhoury, 2015; Walsh et al., 2011). ID, characterized by
significant cognitive dysfunction and adaptive behavior deficits, is seen in approximately
75% of individuals with ASD (Ellison et al., 2013). Several mouse models for ASD/ID
have been generated in addition to Arid1b knockout mice. One of the most frequent
genetic causes of ASD is fragile X syndrome (FXS), caused by expanded CGG repeats
in the 5’ untranslated region of the fragile X mental retardation 1 gene (FMR1), leading
to loss of the FMR1 protein (Harris et al., 2008; Kogan et al., 2009). Fmr1 knockout
mouse models exhibit several behavioral abnormalities recapitulated in human ASD
patients, including social and cognitive deficits, anxiety-like behaviors, and epilepsy
(Gibson et al., 2008; McNaughton et al., 2008; Selby et al., 2007; Yabe et al., 2004).
Other mouse models of ASD that have been generated and extensively studied are

33
knockouts of neuroligin 3 (Nlgn3), neuroligin 4 (Nlgn4), contactin-associated protein-like
2 (Cntnap2), and SH3 and multiple ankyrin repeat domains 3 (Shank3) genes. These
mice exhibit behavioral abnormalities consistent with human patients with mutations in
these genes, including social deficits, stereotyped behaviors, and increased seizure
susceptibility (Jamain et al., 2008; Peca et al., 2011; Penagarikano et al., 2011). Rett
syndrome, which is characterized by ASD-like behavior, learning impairments, motor
deficits, and epilepsy, is caused mutations in the gene encoding methyl-CpG binding
protein 2 (MECP2), leading to loss of MECP2 protein expression (Chahrour and Zoghbi,
2007). Mecp2 knockout mice have similar behavioral phenotypes to human patients
(Calfa et al., 2011; Chen et al., 2001; Guy et al., 2001). Additionally, Angelman
syndrome, caused by loss of the maternal ubiquitin protein ligase E3A (UBE3A) allele,
has a frequent co-morbidity with autism (Steffenburg et al., 1996; Trillingsgaard and JR,
2004). Mouse models exhibit phenotypes similar to human patients, including high
susceptibility to seizures due to dysfunction in inhibitory activity (Wallace et al., 2012).
While the genetic causes of ASD and related disorders are highly heterogenous,
comparisons of neural and behavioral deficits across these diverse models can hopefully
provide insight on converging mechanisms underlying the pathogenesis.
1.4.2 Current and prospective therapies
There is no treatment tool available for the core symptoms of ASD and ID.
Current pharmacologic strategies focus on GABAergic modulation to normalize the
deficits in inhibitory activity. GABA agonists to enhance inhibition, such as
benzodiazepines and anticonvulsants, have been useful in treating some behaviors
associated with ASD in humans, including aggressive and hyperactive behaviors (Belsito
et al., 2001; Di Martino and Tuchman, 2001). Use of clonazepam, a positive modulator
of the GABAA receptor, to enhance inhibitory activity in mouse models has also been
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successful in rescuing both behavioral phenotypes and inhibitory activity deficits (Han et
al., 2012; Jung et al., 2017). In some cases, excessive inhibitory activity has been
observed in ASD/ID and related disorders (Fernandez et al., 2007). Treatment with a
GABA antagonist in mouse models with elevated inhibition successfully rescued neural
and behavioral deficits both in adolescents and into adulthood (Cui et al., 2008). Several
studies have also implicated the contribution of brain-derived neurotrophic factor (BDNF)
signaling deficits to the pathology of ASD and ID (Hur and Zhou, 2010; Jiang et al.,
2005; Ka et al., 2014a; Witte and Bradke, 2008), and as such, ongoing research also
focuses developing pharmacologic treatments targeting this pathway.
In addition to pharmacologic treatments, a major focus in the field has shifted to
genetic treatment strategies. Gene therapy relies on virus-mediated delivery of the
affected gene to normalize its expression in the brain. A handful of studies have
demonstrated that normalizing expression and function of an affected gene during
postnatal development and adulthood can rescue the neurological deficits associated
with ASD and ID (Daily et al., 2011; Guy et al., 2007; Mei et al., 2016). Use of adenoassociated viruses (AAVs) for gene therapy is currently being used in clinical or preclinical trials for various CNS disorders, including Alzheimer’s, Parkinson’s, epilepsy, and
pain disorders (Hocquemiller et al., 2016). The success of AAVs for gene delivery in
CNS disorders together with the ability to rescue ASD/ID phenotypes after early
developmental stages provides a promising outlook on the future of genetic therapy. A
prominent shortcoming of these strategies is that they are currently non-specific and aim
to target the brain as a whole. As we continue to gain a better understanding of the
cellular and molecular events that lead to these neurodevelopmental disorders, we can
develop more targeted therapeutic strategies, such as targeting specific cell types and
circuits.
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1.5 Role of interneurons in neurodevelopmental disorders
1.5.1 Excitatory/Inhibitory balance
While the pathology underlying ASD and ID is still largely unknown, it has been
hypothesized that individuals affected exhibit disproportionately weak levels of inhibition
or high levels of excitation in brain circuits regulating social, communication, and
cognitive functions (Gogolla et al., 2009; Nelson and Valakh, 2015; Rubenstein and
Merzenich, 2003). High levels of circuit plasticity during critical periods of early
development allow neurons to form these functional connections through an experiencedependent phase of maturation (Gogolla et al., 2009). A controlled balance between
excitation and inhibition (E/I balance) is formed during this period, and maintaining this
balance is essential for proper circuit function (Lee et al., 2017). Several factors
contribute to the regulation of normal neuronal E/I balance, including excitatory/inhibitory
synapse development, synaptic transmission and plasticity, and proper signaling
pathways that mediate these functions (Gatto and Broadie, 2010; Lee et al., 2017).
Dysfunction in these processes, due to various genetic mutations or environmental
factors, leads to a disrupted E/I balance and is implicated in several neurodevelopmental
disorders (Gatto and Broadie, 2010; Rubenstein and Merzenich, 2003; Zikopoulos and
Barbas, 2013). Converging evidence from several animal and human studies suggest
that cellular anatomical features of neurons, such as axon and spine development, also
contribute to changes in circuit connectivity that leads to E/I imbalances (Zikopoulos and
Barbas, 2013). While the E/I imbalance theory is a convincing model of the pathogenesis
of neurodevelopmental disorders, it is important to acknowledge that it is an overly
simplistic model. Individual microcircuits throughout brain regions exhibit different
combinations of excitation and inhibition levels and sources of input, which may affect
neuronal functions differently (Rubenstein and Merzenich, 2003). However, despite
these complexities, many signaling pathways and activity-dependent processes that
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affect excitatory and inhibitory transmission are conserved in circuits across multiple
brain regions (Nelson and Valakh, 2015). It is not unreasonable to assume that
neurodevelopmental disorders may similarly affect excitatory or inhibitory synaptic
function throughout distributed areas of the brain.
It is also important to note a recent study that presents an alternate perspective
to the E/I theory of autism. Antoine et al. examine the hypothesis that in increased E/I
ratio causes hyperexcitability and excess spiking in four different mouse models of
autism (Antoine et al., 2019). While they verified an increase in the E/I ratio, this did not
cause an excess of synaptic depolarization or spiking of pyramidal cells, suggesting that
the common assumption that an increase in the E/I synaptic conductance ratio
necessarily predicts increased spiking excitability is incorrect (Antoine et al., 2019).
Given these results, an alternative explanation suggests that various ASD mutations
alter cortical spiking activity, which secondarily engages an E/I homeostasis mechanism
to restore normal cortical firing rate, thus altering the E/I balance. ASD symptoms may
still arise as a result of imperfect or insufficient homeostasis.
1.5.2 Interneuron deficits in neurodevelopmental disorders
Perturbation of the well-balanced excitatory and inhibitory components can lead
to life-long cognitive, social, and emotional disabilities. Impairments in GABAergic
interneuron development has been implicated in several neurodevelopmental disease
states. Many studies have shown that mutations in ASD/ID-associated genes frequently
alter GABAergic function. Mouse models with gain of function mutations in Nlgn3 exhibit
elevated levels of inhibitory activity (Tabuchi et al., 2007), and mice with loss of function
mutations in the Nlgn4 gene show a reduction of inhibitory activity (Jamain et al., 2008;
Zhang et al., 2009). Truncating mutations in several genes affecting GABA receptors
have also been shown in human ASD/ID patients (Piton et al., 2013), and post-mortem
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brains of these patients exhibit a reduction in GABA receptors (Fatemi et al., 2009;
Oblak et al., 2011). Mouse models of Rett syndrome have consistently exhibited a
reduction in expression of Gad1, Gad2, and GABA, leading to decreased inhibitory
activity (Chen et al., 2001; Guy et al., 2001). FXS mouse models show decreased
inhibitory neuron output as well as fewer GABAergic neurons (Curia et al., 2009; Gibson
et al., 2008; Selby et al., 2007). Angelman syndrome has also been shown to have
reduced inhibition onto pyramidal neurons, resulting in decreased excitatory outputs in
both mouse models and humans (Wallace et al., 2012). Human patients with
schizophrenia, another neurodevelopmental disorder caused by loss of function
mutations in genes encoding neuregulin 1 (NRG1) and its receptor tyrosine kinase
ERBB4, also show a reduction in Gad1, Gad2, and GABA expression leading to
inhibitory activity deficits (Chen et al., 2010; Wen et al., 2010). Additionally, ample
evidence suggests a relationship between PV/SST interneuron abnormalities and the
behavioral deficits seen in ASD and ID. Fmrp, Mecp2, and Nlgn4 knockout mouse
models all exhibit a reduction in PV interneurons within the cortex (Fukuda et al., 2005;
Gogolla et al., 2009; Selby et al., 2007), and post-mortem brains of autistic patients
show a similar decrease in PV subtypes (Hashemi et al., 2017; Zikopoulos and Barbas,
2013). Mice with loss of the phosphatase and tensin homolog (Pten) gene, another ASDassociated gene, have fewer SST interneurons in the cortex (Vogt et al., 2015). Shank1
and Cntnap4 knockout mice both show reduced levels of PV interneuron output
(Karayannis et al., 2014; Mao et al., 2015). Heterozygous and homozygous deletion of
the parvalbumin (Pvalb) gene leads to ASD-associated developmental anatomical
changes and disruption in both excitatory and inhibitory transmission (Wohr et al., 2015).
The high incidence of interneuron abnormalities in these disorders strongly supports the
theory that disruption of the E/I balance contributes to the pathology of
neurodevelopmental disorders.
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1.6 Role of excitatory neurons in neurodevelopmental disorders
1.6.1 Regulation of neurite outgrowth
Neurite development can be divided into three main steps: axon and dendrite
specification during neuronal polarization, neurite growth and guidance, and neurite
branching and synaptogenesis (Barnes and Polleux, 2009; Lewis et al., 2013). The basis
of mediating these steps is dynamic organization of the cytoskeleton. Actin and
microtubule dynamics play a crucial role during neuronal polarization. The primary way
for the axon to differentiate from other neurites that become dendrites is to exhibit
different cytoskeleton dynamics (Barnes and Polleux, 2009; Lewis et al., 2013; Shi et al.,
2003). The tip of the neurite that becomes the axon contains unstable actin filaments
that are more dynamic and flexible than those in other neurites (Witte and Bradke,
2008). This polarized destabilization of actin allows invasion of distally polymerizing MTs
into the growth cone, promoting preferential elongation of the axon (Lalli, 2014; Witte
and Bradke, 2008). Several microtubule-associated proteins (MAPs) play a critical role in
the stabilization and polymerization of MTs. Different MAPs are distinctly localized to
neurites that become dendrites and the neurite to become the axon via selective motor
protein transport, contributing to the establishment of polarity (Lewis et al., 2013; Namba
et al., 2015). Dendrite-specific MAP1B and axon-specific Tau and collapsing response
mediator protein 2 (CRMP2) prevent interactions between microtubule-severing proteins
and MTs, thus stabilizing them and promoting extension at the distal plus end. Another
microtubule associated protein, adenomatous polyposis coli (APC), is expressed in both
axons and dendrites (Lalli, 2014; Lewis et al., 2013). Rather that nonstop outgrowth,
neurites grow in a noncontinuous fashion, undergoing frequent pauses and retractions,
followed by resumed forward growth (Lewis et al., 2013). This process facilitates the
complex branching observed in mature neurons. Neurite branching allows for a single
neuron to connect to a broad range of postsynaptic targets and receive several inputs.
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Branching occurs through two different mechanisms. The first is through splitting of the
growth cone, and is the primary mechanism utilized by axons (Luo and O'Leary, 2005).
The second, known as interstitial branching, occurs through the formation of collateral
branches directly along the neurite shaft (Gomez et al., 2001; Gomez and Spitzer, 1999;
Luo and O'Leary, 2005). F-actin filaments accumulate along the neurite shaft and serve
as nucleators to give rise to a protrusion. MTs along the main shaft get fragmented,
followed by invasion and elongation within the protrusion (Lewis et al., 2013). Most
dendritic branching occurs through interstitial branching. Time lapse imaging has shown
that this type of branching occurs after the pausing phase of neurite extension, shortly
before continuing the forward growth (Catalano and Shatz, 1998). Interestingly, the
plasticity of cytoskeletal dynamics in neuronal polarity and outgrowth does not end
during early neuronal development. After the severing of an axon, a dendrite still has the
capacity to become a new axon with relocalization of polarity molecules (Barnes and
Polleux, 2009; Witte and Bradke, 2008).
Several factors influence the regulation of cytoskeletal dynamics. Intracellular
signaling pathways are the primary regulators of cytoskeletal dynamics that mediate
neurite development. BDNF neurotrophic signaling is a master regulator of neurite
development (Hur and Zhou, 2010; Yoshimura et al., 2005). Tropomyosin receptor
kinase B (TrkB) activation by BDNF leads to a downstream intracellular signaling
cascade. Phosphoinositide 3-kinase (PI3K) becomes activated by phosphorylation,
which subsequently phosphorylates and activates protein kinase B (AKT), which then
phosphorylates GSK3β rendering it inactive (Hur and Zhou, 2010; Jiang et al., 2005).
This intracellular signaling pathway controls MT stabilization and elongation by acting on
proteins involved in MT dynamics, including CRMP2, Tau, MAP1B, and APC (Skene,
1989; Yoshimura et al., 2005). During establishment of polarity, phosphorylated GSK3β
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(p-GSK3β), the inactive form of the protein, accumulates specifically at the tip of the
neurite that becomes the nascent axon, while non-phosphorylated GSK3β is expressed
throughout other neurites (Jiang et al., 2005; Skene, 1989). Activation of GSK3β in
dendrites above basal levels leads to activation of the ubiquitin/proteasome protein
degradation system, which causes local degradation of CRMP2, Tau, and other axonspecific proteins within the dendritic compartment (Barnes and Polleux, 2009; Hur and
Zhou, 2010). When CRMP2, APC, and Tau are phosphorylated by GSK3β, their ability
to bind to tubulin dimers is abolished, which inhibits neurite elongation (Skene, 1989;
Yoshimura et al., 2005). Inactivation of GSK3β in the nascent axon thus promotes
association between CRMP2/APC/Tau and microtubule plus ends, stabilizing the
growing ends of MTs to promote axon elongation. Phosphorylation of MAP1B by active
GSK3β renders MAP1B more stable, maintaining MTs in a dynamic state and promoting
extension of dendrites (Hur and Zhou, 2010; Yoshimura et al., 2005). During genesis of
cortical projection neurons, axon outgrowth begins during migration, and rapid extension
and branching of the axon continues after migration ends. In contrast, dendrite growth
and branching does not begin until after cells have reached their location in the cortex,
and dendritic growth occurs 5-10 times slower than axon growth (Azzarelli et al., 2014;
Lalli, 2014). Once the neuron reaches the target location, dendrites gradually begin to
express the phosphorylated form of GSK3β, though at much lower concentrations than
in axons (Hur and Zhou, 2010). The combination of active and inactive forms results in
stabilization of APC in addition to MAP1B, contributing to increased dendrite growth.
Studies have shown that overexpression of p-CRMP2 and p-Tau leads to reduced axon
growth and branching (Jung et al., 2015; Kim et al., 2009; Yoshimura et al., 2005).
Additionally, expression of a constitutively active form of GSK3β results in inhibition of
axon formation. In contrast, inhibition of GSK3β activity results in formation of multiple
axons (Jiang et al., 2005; Kim et al., 2006). These manipulations further underscore the
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importance of molecular polarization during the specification of axons and dendrites.
Interestingly, GSK3β knockout mouse models do not exhibit deficits in neurite
development, but mice lacking both GSK3α and GSK3β isoforms do, suggesting a
compensatory mechanism of GSK3α when GSK3β is lost (Kim et al., 2006).
In addition to BDNF signaling, multiple other intracellular pathways converge
onto GSK3β and affect neurite development. mTOR is another downstream component
of the BDNF signaling pathway. Activation of PI3K and AKT leads to inhibition of the
tuberous sclerosis complex 2 (TSC2), a negative regulator of mTOR, thus activating
mTOR and its downstream targets eukaryotic translation initiation factor 4E-binding
protein (4EBP) and ribosomal protein S6 kinase beta-1 (S6K) (Barnes and Polleux,
2009; Hur and Zhou, 2010). Evidence suggests that mTOR activation is localized
specifically within the neurite to become the axon and initiates translation of axonspecific microtubule-associated proteins CRMP2 and Tau (Hur and Zhou, 2010; Morita
and Sobue, 2009). When GSK3β is in its active form, it activates TSC2, thus inhibiting
activity of mTOR. Upon phosphorylation and inactivation of GSK3β, activity of mTOR is
increased (Ka et al., 2014a). This suggests a direct interplay between mTOR and
GSK3β that enhances downstream signaling to maintain proper cytoskeletal dynamics in
neurites. Additionally, signaling involving the partitioning defective protein 3/6/protein
kinase C (PAR3/PAR6/PKC) complex is essential for establishing proper specification of
axons and dendrites (Barnes and Polleux, 2009; Hur and Zhou, 2010). PAR3 and PAR6
are localized at the tips of all neurites prior to polarization, and later become enriched in
the axon growth cone to aid in axon elongation (Lewis et al., 2013; Shi et al., 2003).
Inactivation of GSK3β is required to mediate targeting of these components to the axon
and to initiate formation of the complex (Shi et al., 2003). GSK3β-mediated
phosphorylation of MACF1 in neurites to become dendrites also modulates actin and MT
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dynamics and regulates dendritic arborization (Moffat et al., 2017). Mice with loss of
MACF1 exhibited altered cytoskeleton arrangements in neurites and showed decreased
dendritic arborization in cortical and hippocampal neurons (Ka and Kim, 2016). GSK3β
also plays a role in regulating Wnt/β-catenin signaling, a master regulator of
neurodevelopment. GSK3β forms a destruction complex with other proteins and targets
β-catenin for degradation. In the presence of Wnt, the complex is then recruited to the
frizzled receptor, inhibiting GSK3β and allowing accumulation of β-catenin and
subsequent targeting to the nucleus to initiate transcription of cytoskeletal-associated
genes (Hur and Zhou, 2010; Namba et al., 2015). The complex intracellular signaling
network regulating cytoskeleton dynamics and neurite outgrowth is illustrated in Figure
1.4.
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Figure 1.4 Intracellular signaling pathways regulating neurite outgrowth
BDNF neurotrophic signaling is a master regulator of cytoskeleton dynamics and neurite
outgrowth. GSK3β, a downstream component of BDNF signaling,acts as a hub while also
playing a role in multiple other intracellular pathways regulating these processes, including
mTOR, PAR complex, and Wnt/β-catenin signaling.
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Interestingly, once neurite outgrowth is complete, the machinery responsible
remains at the proximal end of the axon/dendrite near the soma (Namba et al., 2015).
This allows for a neuron to regenerate a neurite if it gets severed. In culture, if an axon is
severed very near the soma at the proximal end, it is unable to regenerate (Sengottuvel
et al., 2011). Instead, one of the dendrites becomes the new axon. When severed more
distally, the axon regrows back to its original length (Sengottuvel et al., 2011).
Additionally, in vivo studies of nerve injury show that after crushing or severing the
nerve, MT stabilization is able to induce complete axon regeneration (Hellal et al., 2011).
Furthermore, with loss of BDNF signaling downstream of PI3K, axon regeneration is
unable to occur after nerve injury (Park et al., 2008). These studies indicate that
although adult neurons lose much of their plasticity after fully maturing, neurite deficits
may still be salvageable beyond the critical developmental period by normalizing
neurotrophic signaling and cytoskeletal dynamics.
1.6.2 Neuron maturation deficits in neurodevelopmental disorders
Deficits in neuron maturation have been implicated in the pathology of many
neurodevelopmental and psychiatric disorders (Chapleau et al., 2009; Fiala et al., 2002;
Kaufmann and Moser, 2000; Machado-Salas, 1984; Penzes et al., 2011). In addition to
neurite outgrowth, dendritic spine development is an essential step in neuron maturation,
as spines are the main site of excitatory input and form the basis of synaptic circuitry
(Bourne and Harris, 2008; Harris and Kater, 1994). Post-mortem brains of human ASD
and ID patients frequently exhibit altered axon fibers of the corpus callosum, abnormal
dendritic arborization, and increased spine density in cortical pyramidal neurons (Aoki et
al., 2017; Gilbert and Man, 2017; Hutsler and Zhang, 2010; Huttenlocher, 1974;
Kucharsky Hiess et al., 2015; Martínez-Cerdeño, 2017; Penzes et al., 2011). Rett
syndrome patients also have reduced dendritic arborization and abnormal spine
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development in the cortex (Armstrong, 2005; Belichenko et al., 1994; Kaufmann and
Moser, 2000). Abnormal spine development is a primary characteristic of cortical
neurons in patients with Down syndrome, which is the most common cause of ID
(Kaufmann and Moser, 2000). Individuals affected generally have reduced spine density,
spine size, and abnormal spine morphology, such as short stubby spines or long
filopodia-like spines (Marin-Padilla, 1976; Roberts et al., 1996). Post-mortem brains from
patients with tuberous sclerosis, a condition frequently co-occurring with ASD, have a
similar atypical morphology and reduction in spine number and size (Machado-Salas,
1984). Additionally, FXS is characterized by an increase in spine density (Fiala et al.,
2002; Kaufmann and Moser, 2000).
Mouse models of various neurodevelopmental disorders recapitulate several of
these deficits seen in human patients. Downregulation of thousand and one amino acid
kinase 2 (Taok2), an ASD susceptibility gene, disrupts the formation of basal dendrites
and axonal projections in cortical pyramidal neurons (de Anda et al., 2012). In a mouse
model of Rett syndrome, Mecp2 deficient neurons have deficits in neurite outgrowth due
to altered MT dynamics (Nectoux et al., 2012). Mecp2 deficient mice also exhibit
reduced cortical thickness, reduced spine density, abnormal dendritic development, and
delayed neuronal maturation within the cortex (Fukuda et al., 2005; Irwin et al., 2002;
Jentarra et al., 2010). Mecp2 duplication syndrome, a neurodevelopmental disorder
characterized by ID, autism, motor abnormalities, and epilepsy, results in increased
spine density and dendritic overgrowth (Jiang et al., 2013). Overexpression of the Down
syndrome-associated gene dual specificity tyrosine phosphorylation regulated kinase 1a
(Dyrk1a) leads to reduced spine density and abnormal spine morphology caused by
changes in the dynamic reorganization of the cytoskeleton (Martinez de Lagran et al.,
2012; McKinney et al., 2005). Multiple mouse models of FXS also exhibit increased
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dendritic spine density and atypical spine dynamics and morphology (Han et al., 2015;
Nagaoka et al., 2016).
Additional studies have suggested that BDNF signaling is involved in the
pathology of various neurodevelopmental disorders. Haploinsufficiency of the chromatin
regulator gene ankyrin repeat domain 11 (Ankrd11) has been associated with ASD and
ID (Isrie et al., 2012; Lo-Castro et al., 2013; Sirmaci et al., 2011). Knockdown of the
gene results in deficits in dendritic arborization and spine development as well as
reduced BDNF signaling and decreased expression of downstream targets (Ka and Kim,
2018). Altered BDNF signaling has also been implicated in several other established
mouse models of FXS, Rett syndrome, and Angelman syndrome (Cao et al., 2013;
Chang et al., 2006; Lauterborn et al., 2007). Changes in GSK3 signaling activity has
been associated with altered neurite development and ASD/ID-related behaviors (Jiang
et al., 2005; Jung et al., 2015; Kim et al., 2006; Lalli, 2014), and thus GSK3 has been a
common therapeutic target for various psychiatric drugs (Hur and Zhou, 2010).
Together, these studies indicate that deficits in neurite growth and synaptogenesis,
mediated by altered BDNF signaling, is a likely component of the underlying pathology of
ASD/ID and related disorders.
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2.1 Abstract
Inhibitory interneurons are essential for proper brain development and function.
Dysfunction of interneurons is implicated in several neurodevelopmental disorders,
including autism spectrum disorder (ASD) and intellectual disability (ID). We have
previously shown that Arid1b haploinsufficiency interferes with interneuron development
and leads to social, cognitive, and emotional impairments consistent with ASD and ID. It
is unclear, however, whether interneurons play a major role for the behavioral deficits in
Arid1b haploinsufficiency. Furthermore, it is critical to determine which interneuron
subtypes contribute to distinct behavioral phenotypes. In the present study, we
generated Arid1b haploinsufficient mice in which a copy of the Arid1b gene is deleted in
either parvalbumin (PV) or somatostatin (SST) interneurons, and examined their ASDand ID-like behaviors. We found that Arid1b haploinsufficiency in PV or SST
interneurons resulted in distinct features that do not overlap with one another. Arid1b
haploinsufficiency in PV neurons contributed to social and emotional impairments, while
the gene deletion in the SST population caused stereotypies and cognitive dysfunction.
These findings demonstrate a critical role of interneurons in Arid1b haploinsufficient
pathology and suggest that PV and SST interneurons may have distinct roles in
modulating neurological phenotypes in Arid1b haploinsufficiency-induced ASD and ID.
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2.2 Introduction
Autism spectrum disorder (ASD) and intellectual disability (ID) are highly
prevalent neurodevelopmental disorders, characterized by social communication
impairments and cognitive dysfunction, respectively (Ellison et al., 2013; Fakhoury,
2015). Emotional disturbance such as aggressive behavior, depression, and anxiety is
another significant aspect of ASD and ID (Benson and Brooks, 2008; DeFilippis, 2018;
Fitzpatrick et al., 2016; Matson and Nebel-Schwalm, 2007; van Steensel et al., 2013;
White et al., 2009). While behaviors of ASD and ID are relatively well characterized, the
neuropathogenesis of these conditions is poorly understood. Accordingly, no
pharmacologic or genetic interventions are available for ASD or ID. Haploinsufficiency of
the AT-rich interactive domain 1B (ARID1B) gene has been shown to cause ASD and ID
in humans (Halgren et al., 2012; Hoyer et al., 2012; Santen et al., 2012a). ARID1B is a
component of the Brg/Brm associated factor (BAF) chromatin remodeling complex in the
brain (Tang et al., 2010; Wang et al., 2004). It binds to DNA through its AT-rich DNAbinding domain and alters chromatin structure, facilitating transcription factor access and
regulating gene expression.
Many neurodevelopmental disorders exhibit improper inhibitory interneuron
development, resulting in excitatory/inhibitory (E/I) imbalance (Marin, 2012; Nelson and
Valakh, 2015; Ramamoorthi and Lin, 2011). We have previously generated an Arid1b
mouse model and showed that Arid1b haploinsufficient (Arid1b+/-) mice recapitulate ASD
and ID behavior (Jung et al., 2017). Importantly, Arid1b haploinsufficient mice exhibit a
reduction and abnormal distribution of interneurons as well as abnormal inhibitory
synaptic activity in the cerebral cortex (Jung et al., 2017). No clear anatomical or
physiological phenotype has been found in excitatory neurons, suggesting a more
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prominent effect on interneuron abnormalities in potentially creating a range of social,
intellectual, and emotional deficits in Arid1b haploinsufficient mice.
Thus, we hypothesized that Arid1b haploinsufficiency-induced neurological
behavior is mediated by interneurons. To test this idea, we conditionally knocked out the
Arid1b gene in parvalbumin (PV) and somatostatin (SST) interneurons using specific
Cre-drivers and examined neurological behaviors in interneuron-specific Arid1b
haploinsufficient mice. PV and SST neurons are the most populous interneuron subtype
in the cortex, each constituting 30%-40% of the inhibitory interneuron population (Rudy
et al., 2011). These subtypes exhibit a range of different morphological,
electrophysiological, and molecular properties, and appear to play roles in distinct circuit
functions (Kepecs and Fishell, 2014; Klausberger and Somogyi, 2008). Little is known
regarding how these individual interneuron subtypes differentially modulate various
behaviors. Here, we show that Arid1b haploinsufficiency in PV and SST neurons has
distinct, non-overlapping behavioral phenotypes that recapitulate behavioral deficits
seen in Arid1b haploinsufficient mice. PV interneurons with Arid1b haploinsufficiency
alter social and emotional behaviors, while SST interneurons of the gene mutation affect
cognitive and stereotyped behaviors. Our findings demonstrate that interneurons
mediate Arid1b haploinsufficiency-induced behaviors and suggest distinct individual
roles of PV and SST interneurons for ASD and ID behavior.
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2.3 Materials and methods
2.3.1 Arid1b conditional knockout mice
The Arid1b-floxed allele (Jung et al., 2017) was crossed with either the PV-Cre
(B6;129P2-Pvalbtm1(cre)Arbr/J; JAX 008069) or SST-Cre (B6N.Cg-Ssttm2.1(cre)Zjh/J; JAX
018973) allele. After weaning, all mice were group housed (no more than 5 mice per
cage) as a mix of genotypes on a 12-hour light/dark cycle. All mice used as “stranger
mice” in behavioral assays were housed separately from experimental mice. All
husbandry and experimental procedures were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of Kent State University and the
University of Nebraska Medical Center.
2.3.2 Immunostaining
Immunostaining of brain sections was performed as described previously (Ka
and Kim, 2018; Ka et al., 2016b) . The following primary antibodies were used: antiParvalbumin (Millipore, Rabbit, AB1572), anti-Arid1b (Abcam, Mouse, ab57461), and
anti-Somatostatin (Millipore, Rat, AB1572). 4′,6-diamidino-2-phenylindole (DAPI; Sigma)
was used for counterstaining. Appropriate secondary antibodies conjugated with Alexa
Fluor dyes (Invitrogen) were used to detect primary antibodies. All slides were visualized
and imaged under FV3000 (Olympus) fluorescent confocal microscope system. The
levels of protein expression were quantified by measuring fluorescence intensities using
NIH ImageJ.
2.3.3 Behavioral assays
All behavior assays were performed during the light cycle. Health conditions,
including weight, activity, and feeding were checked before assays. Male and female
mice at ages 2-4 months were used for all behavior assays, and all assays were done in
the same chronological order and timeframe. For social behavior assays, only male-
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male or female-female social interactions were examined to avoid interference of malefemale sexual interactions and estrous cycle timing. All behavioral assays were done
blind to genotypes, with age-matched littermates.
2.3.4 Three-chamber test
A rectangular, transparent Plexiglas box (60 x 40 cm, Ugobasile) divided by walls
with openings into three equal-sized compartments was used. Before starting any
behavior testing, test mice were habituated to the empty apparatus for 5 minutes. For
sociability testing, the test mouse was placed in the center chamber (chamber 2), an
empty wire enclosure was placed in chamber 1, and an unfamiliar stimulus mouse
designated as “stranger 1” was placed in a wire enclosure in chamber 3. The test mouse
was allowed to explore the entire apparatus for 10 minutes. For the social novelty test,
the stranger 1 mouse in its wire enclosure was randomly placed in either chamber 1 or
3, and a novel mouse designated as “stranger 2” was taken from a different home cage
and placed in the empty wire enclosure within the other flanking chamber. The test
mouse was placed back into chamber 2 and allowed to explore the original stranger 1 or
the novel stranger 2 for 10 minutes. Video recordings were taken of the test mouse
during both sociability and social novelty tests. Time spent interacting with each wire
enclosure was analyzed using video tracking EthoVision XT 7 software (Noldus). Both
stranger mice were age- and sex-matched wild type mice.
2.3.5 Grooming assessment
A test mouse was placed in a clear plastic cage (17 x 32 x 14 cm) with normal
housing bedding. Food and water were removed. The mouse was habituated to the cage
for 10 minutes, followed by a 10-minute testing period in which the mouse was allowed
to explore the cage freely. The movement of the mouse was recorded by a camera
during the testing period, and the total time spent grooming was analyzed. Head
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washing, body grooming, genital/tail grooming, and paw and leg licking were all
considered grooming behavior.
2.3.6 Open field test
A test mouse was placed near the wall of a 35 x 42 cm open field arena and
allowed to explore freely for 5 minutes. The movement of the mouse during the 5-minute
testing period was recorded by a camera. The number of entries into and the overall
time spent in the center of the arena (15 x 15 cm imaginary square) were analyzed using
EthoVision XT 7 software (Noldus). The open field arena was cleaned with ethanol and
dried between each trial. The mice were not habituated to the arena before testing.
2.3.7 Elevated plus maze test
The elevated plus maze was performed as previously described (Jung et al.,
2017) (Jung et al., 2016). The apparatus (EB Instrument) was elevated 45 cm above the
floor, and the test mouse was placed on the central platform (5 x 5 cm). The mouse was
allowed to freely explore either the two open arms (35 x 5 cm) or two enclosed arms (35
x 5 x 15 cm) for 5 minutes. The number of entries into and total time spent in open and
closed arms were recorded.
2.3.8 Tail suspension test
A test mouse was suspended from 60 cm above the surface of a table using
adhesive tape at the tip of the tail. The mouse was acclimatized for 1 minute, followed by
a 5-minute testing period in which the total duration of immobility was measured.
Passive, completely motionless hanging was considered immobile behavior.
2.3.9 Forced swim test
A test mouse was placed into a plastic cylinder (20 cm height, 17 cm diameter)
filled with room temperature water to a depth of 10 cm. The mouse was acclimatized for
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1 minute, followed by a testing period of 5 minutes in which the duration of immobility
was measured. A mouse floating motionlessly was considered immobile.
2.3.10 Novel object recognition test
A test mouse was placed into an empty open field arena (35 x 42 cm) and
allowed to explore freely during a 5-minute habituation period. The mouse was then
removed and two objects of similar size (10.5 x 4.5 x 2.5 cm), but different shape and
color, were placed in opposite corners of the arena, 7 cm from the side walls. The
mouse was placed back into the arena and allowed to explore the two objects for 10
minutes. The mouse was returned to its home cage, and after 6 hours, one object was
replaced with a novel object of a similar size but different shape and color than the
previous object. The same test mouse was placed back in the arena to explore the
familiar and novel objects for another 10 minutes while being recorded by a camera. The
amount of time the mouse spent interacting with the two objects was analyzed using
EthoVision XT software (Noldus).
2.3.11 Rotarod test
Mice were placed on rotating drums (3 cm diameter) of an accelerating rotarod
(Rotamex 4/8, Columbus Instruments International). Three 5-minute trials per day (at
constant speeds of 4, 8, and 12 rpm) were performed for three days of training. The
following nine testing days consisted of one test trial per day, with the speed of the
rotarod accelerating from 4 to 40 rpm over a 5-minute period. The time taken for the
mouse to fall off the rotating rod was measured for each trial and recorded as its latency
to fall.
2.3.12 Morris water maze test
A circular tank 110 cm in diameter and 91 cm in height (San Diego Instruments)
was filled with water and divided into four equal quadrants (Q1-4) by lines drawn on the
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floor. Visual cues of different color and shape were present on the wall of each quadrant
as a spatial reference. A 10 cm circular plexiglass platform was submerged 1 cm deep in
Q2, hidden from the mice. For each trial, test mice were placed at the perimeter of the
tank in one of four quadrants. Four trials were performed per mouse per day during a
ten-day training phase. Each trial ended when the mouse climbed onto and remained on
the hidden platform for ten seconds. The mouse was given 20 seconds to rest on the
platform between trials. The time taken by the mouse to reach the platform was recorded
as its latency. The time for four trials was averaged and recorded as a result for each
mouse on each day. To test memory retention, the mice were subjected to a single 60second probe trial on day 11. The hidden platform was removed and each mouse
started the trial from Q4. The swim path was video recorded, and the number of annulus
crossings, velocity, and swim distance were analyzed using EthoVision XT 7 tracking
software (Noldus).
2.3.13 Statistical analysis
Normal distribution was tested using the Kolmogorov-Smirnov test and variance
was compared between populations. Statistical significance was determined using twotailed unpaired Student’s t-tests for two population comparisons or repeated measures
ANOVA. Data were analyzed using GraphPad Prism and presented as means ± SEM.
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2.4 Results
2.4.1 Arid1b haploinsufficiency in PV and SST interneurons have distinct effects on
social and stereotyped behaviors
Our previous study has shown that Arid1b haploinsufficient (Arid1b+/-) mice
exhibit social, emotional, and cognitive deficits as seen in ASD and ID (Jung et al.,
2017). To determine the contributions of PV and SST interneurons to the ASD- and IDlike behaviors observed in Arid1b+/- mice, we generated two lines of conditional knockout
mice lacking one copy of Arid1b in either PV (F/+; PV-Cre) or SST (F/+; SST-Cre)
neurons by crossing floxed Arid1b mice with PV-Cre or SST-Cre mice, respectively. We
then characterized these mice with multiple behavioral assays. Arid1b wild-type
littermates with a Cre driver (+/+; PV-Cre or +/+; SST-Cre) were used as controls. To
verify successful generation of conditional knockout mice, we examined ARID1B
expression by co-labeling cortical sections with antibodies to ARID1B and PV or ARID1B
and SST (Fig. 2.1). The level of ARID1B was decreased in the F/+; PV-Cre cortex by
42% compared to the protein level in control samples (Fig. 2.1a, b). A reduction in the
ARID1B level by 48% was also observed in F/+; SST-Cre tissues (Fig. 2.1c, d). F/+; PVCre and F/+; SST-Cre mice show no changes in overall body or brain weight compared
to littermate controls (Fig. 2.2-2.3).
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Figure 2.1 ARID1B expression in PV and SST interneurons of Arid1b
mutant mice
a. Cortical sections from P60 +/+; PV-Cre and F/+; PV-Cre mice were coimmunolabeled with antibodies to ARID1B and PV. b. Quantification of ARID1B
levels in PV interneurons of +/+; PV-Cre and F/+; PV-Cre mice (***p<0.0001; n=4
for +/+; PV-Cre mice and n=5 for F/+; PV-Cre mice; two-tailed Student’s t test). c.
Cortical sections from P60 +/+; SST-Cre and F/+; SST-Cre mice were coimmunolabeled with ARID1B and SST. d. Quantification of ARID1B levels in SST
interneurons of +/+; SST-Cre and F/+; SST-Cre mice (**p=0.0017; n=3 for +/+;
SST-Cre mice and n=4 for F/+; SST-Cre mice; two-tailed Student’s t test). Data
shown are mean ± SEM.
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Figure 2.3 Body and brain weight with Arid1b haploinsufficiency in
PV neurons
a. Representative images of +/+; PV-Cre and F/+; PV-Cre mice. b. No
change was found in overall body weight between +/+; PV-Cre and F/+;
PV-Cre mice (p=0.435; n=4 mice for +/+; PV-Cre and n=5 mice for F/+;
PV-Cre; two-tailed Student’s t test). c. Representative images of isolated
brains from +/+; PV-Cre and F/+; PV-Cre mice. d. There was no change
in brain weight between +/+; PV-Cre and F/+; PV-Cre mice (p=0.909;
n=4 mice for +/+; PV-Cre and n=5 mice for F/+; PV-Cre; two-tailed
Student’s t test). Data shown are mean ± SEM.
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Figure 2.2 Body and brain weight with Arid1b haploinsufficiency in
SST neurons
a. Representative images of +/+; SST-Cre and F/+; SST-Cre mice. b.
Compared to +/+; SST-Cre mice, F/+; SST-Cre mice showed no
difference in overall body weight (p=0.054; n=3 mice for +/+; SST-Cre
and n=4 mice for F/+; SST-Cre; two-tailed Student’s t test). c.
Representative images of isolated brains from +/+; SST-Cre and F/+;
SST-Cre mice. d. There was no change in brain weight between +/+;
SST-Cre and F/+; SST-Cre mice (p=0.8075; n=3 mice for +/+; SST-Cre
and n=4 mice for F/+; SST-Cre; two-tailed Student’s t test). Data shown
are mean ± SEM.
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We first examined social and stereotyped behaviors. Social impairments and
repetitive behaviors are two core features of ASD. We assessed sociability and social
novelty using the three-chamber test. In the sociability test, +/+; PV-Cre control mice
spent more time in the chamber containing the stranger 1 mouse than in the empty
chamber, whereas F/+; PV-Cre mice showed no preference for either chamber. In the
social novelty test, control mice showed preference for the novel stranger 2 mouse,
whereas F/+; PV-Cre mice spent more time in the chamber containing the more familiar
stranger 1 mouse (Fig. 2.4a). In contrast, F/+; SST-Cre mice showed a preference for
the chamber with the unfamiliar stranger mouse in both the sociability and social novelty
tests, similar to their control counterparts (Fig. 2.4b). We then examined the incidence
of repetitive, stereotyped behaviors by looking at spontaneous grooming. F/+; PV-Cre
mice showed no change in the amount of time spent self-grooming compared to +/+; PVCre controls (Fig. 2.4c). On the other hand, F/+; SST-Cre mice exhibited an increase in
self-grooming time in comparison to control mice (Fig. 2.4c). Together, these results
show that Arid1b haploinsufficiency in PV neurons produces deficits in social behaviors,
while the haploinsufficiency in SST neurons leads to excessive repetitive behaviors.
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Figure 2.4 Social and stereotyped behaviors in F/+; PV-Cre and F/+; SST-Cre mice
a. In the three-chamber test for sociability, F/+; PV-Cre mice spent a similar amount of
time with the empty cage as with the stranger mouse (stranger 1), whereas control
counterparts stayed more time with stranger 1 (+/+; PV-Cre: ***p=0.0002; F/+; PV-Cre:
p=0.3701; n=8 mice for +/+; PV-Cre and n=9 mice for F/+; PV-Cre; two-tailed Student’s t
test). In the three-chamber test for social novelty, F/+; PV-Cre mice spent less time with
the novel stranger (stranger 2) than with the familiar mouse (stranger 1), in contrast to
controls (+/+; PV-Cre: ***p<0.0001; F/+; PV-Cre: ***p=0.0002; n=8 mice for +/+; PV-Cre
and n=9 mice for F/+; PV-Cre; two-tailed Student’s t test). b. F/+; SST-Cre mice showed
increased time spent with stranger 1 compared with the empty cage in the sociability
test, similar to their control counterparts (+/+; SST-Cre: ***p<0.0001; F/+; SST-Cre:
***p<0.0001; n=12 mice for +/+; SST-Cre and n=8 mice for F/+; SST-Cre; two-tailed
Student’s t test). F/+; SST-Cre also spent more time with the novel stranger compared to
stranger 1 during the social novelty test, which is comparable to control mice (+/+; SSTCre: ***p<0.0001; F/+; SST-Cre: ***p=0.0012; n=12 mice for +/+; SST-Cre and n=8 mice
for F/+; SST-Cre; two-tailed Student’s t test). c. F/+; PV-Cre mice exhibited a similar
level of grooming time compared to +/+; PV-Cre mice (p=0.7022; n=8 mice for +/+; PVCre and n=9 mice for F/+; PV-Cre; two-tailed Student’s t test). F/+; SST-Cre mice,
however, showed increased grooming time compared to +/+; SST-Cre mice
(***p<0.0001; n=12 mice for +/+; SST-Cre and n=8 mice for F/+; SST-Cre; two-tailed
Student’s t test). Data shown are mean ± SEM.
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2.4.2 Arid1b haploinsufficiency in PV interneurons, but not SST interneurons, results in
heightened anxiety and depression
Because heightened levels of anxiety and depression are among the most
common comorbid disorders in those with ASD, we next investigated the contribution of
interneurons subtypes in these psychiatric conditions in Arid1b conditional knockout
mice. The open field test was performed to gauge the levels of anxiety in F/+; PV-Cre
and F/+; SST-Cre mice. We found that F/+; PV-Cre mice made fewer entries and spent
less time in the center of the open field compared to +/+; PV-Cre controls, preferring to
stay on the edges and in corners of the arena (Fig. 2.5a, b). However, F/+; SST-Cre
mice showed no differences in anxiety behavior compared to control mice, spending
similar amounts of time in the center of the open field (Fig. 2.5c, d). We crosschecked
the increased anxiety in F/+; PV-Cre mice with the elevated plus maze test. F/+; PV-Cre
mice exhibited greater levels of anxiety compared to controls, making fewer entries and
spending less time in the open arms (Fig. 2.5e). There were no differences in the
amount of time and the number of entries to the open arms between controls and F/+;
SST-Cre mice (Fig. 2.5f). Again, these results suggest PV interneuron dysfunction as a
mediator of Arid1b haploinsufficiency-induced anxiety.
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Figure 2.5 Heightened anxiety in F/+; PV-Cre mice
a. In the open field test, time spent in the center and number of entries into the center
were both decreased in F/+; PV-Cre mice compared to +/+; PV-Cre mice (time in
center: *p=0.0100; center entries: ***p=0.0004; n=11 mice for +/+; PV-Cre and n=12
mice for F/+; PV-Cre; two-tailed Student’s t test). b. Representative tracings of the open
field activity in +/+; PV-Cre and F/+; PV-Cre mice. c. F/+; SST-Cre mice showed a
similar amount of time spent in the center and similar number of entries into the center
compared to +/+; SST-Cre mice in the open field test (time in center: p=0.7632; center
entries: p=0.4300; n=12 mice for +/+; SST-Cre and n=8 mice for F/+; SST-Cre; twotailed Student’s t test). d. Representative tracings of the open field activity in +/+; SSTCre and F/+; SST-Cre mice. e. In the elevated plus maze, F/+; PV-Cre mice exhibited
less time in open arms and fewer entries into open arms compared to control
counterparts (time in open arms: ***p=0.0001; open arm entries: **p=0.0019; n=8 mice
for +/+; PV-Cre and n=9 mice for F/+; PV-Cre; two-tailed Student’s t test). f. F/+; SSTCre mice showed no change in time spent in open arms or total entries into open arms
compared to +/+; SST-Cre mice (time in open arms: p=0.8053; open arm entries:
p=0.4670; n=12 mice for +/+; SST-Cre and n=8 mice for F/+; SST-Cre; two-tailed
Student’s t test). Data shown are mean ± SEM.
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The level of depression was also measured by the tail suspension and forced
swim tests. F/+; PV-Cre mice displayed heightened levels of depression-like behavior,
indicated by an increase in total immobility time in the tail suspension test compared to
control mice (Fig. 2.6a). However, there was no significant difference in immobility time
between F/+; SST-Cre and control mice, suggesting little change in depression behavior.
The forced swim test of F/+; PV-Cre and F/+; SST-Cre mice resulted in a similar pattern
to the tail suspension test. F/+; PV-Cre mice revealed an increased time of immobility
compared to control mice while F/+; SST-Cre mice showed no significant change (Fig.
2.6b). These results demonstrate that PV-specific Arid1b haploinsufficiency leads to a
similar increase in anxiety and depression that is seen in global Arid1b
haploinsufficiency. In contrast, SST-specific Arid1b haploinsufficiency appears to have
no contribution to emotional behaviors.
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Figure 2.6 Increased depression behavior in F/+; PV-Cre mice
a. In the tail suspension test, F/+; PV-Cre mice showed increased
immobility time compared to control mice (**p=0.0055; n=8 mice for
+/+; PV-Cre and n=9 mice for F/+; PV-Cre; two-tailed Student’s t
test). F/+; SST-Cre mice showed no change in immobility time
compared to controls in the tail suspension test (p=0.4381; n=12
mice for +/+; SST-Cre and n=8 mice for F/+; SST-Cre; two-tailed
Student’s t test). b. In the forced swim test, F/+; PV-Cre mice
showed increased immobility time compared to controls
(***p<0.0001; n=8 mice for +/+; PV-Cre and n=9 mice for F/+; PVCre; two-tailed Student’s t test). F/+; SST-Cre mice showed no
change in immobility time in the forced swim test compared to their
controls (p=0.5225; n=12 mice for +/+; SST-Cre and n=8 mice for
F/+; SST-Cre; two-tailed Student’s t test). Data shown are mean ±
SEM.
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2.4.3 Cognitive deficits are caused by Arid1b haploinsufficiency in SST interneurons
Severe cognitive impairments, the primary feature of ID, are found in Arid1b+/mice (Jung et al., 2017). To examine cognitive functions in F/+; PV-Cre and F/+; SSTCre mice, we used several behavior assays of testing different types of learning and
memory. We first performed the novel object recognition test to assess recognition
memory. Control mice spent more time with a novel object than with a familiar object.
F/+; PV-Cre mice behaved similar to controls, approaching and interacting more with the
novel object (Fig. 2.7a). In contrast, F/+; SST-Cre mice showed no preference for
exploring either the familiar or novel object, suggesting impairments in recognition
memory. In the rotarod test for motor learning, both F/+; PV-Cre mice and controls
showed a strong increase in the latency to fall during the three-day training phase (Fig.
2.7b). Throughout the testing phase (days 4 to 12), both control and F/+; PV-Cre mice
revealed a consistent latency to fall. However, F/+; SST-Cre mice did not show the same
increase in the latency to fall compared to controls during the training phase (Fig. 2.7c).
In addition, they showed decreased latencies to fall throughout the testing phase
compared to control mice, suggesting deficits in motor learning ability.
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Figure 2.7 Recognition memory and motor learning deficits in F/+; SST-Cre
mice
a. In the novel object recognition test, both +/+; PV-Cre and F/+; PV-Cre mice
showed greater interaction time with the novel object compared to the familiar
object (+/+; PV-Cre: **p=0.0032; F/+; PV-Cre: ***p=0.0001; n=11 mice for +/+;
PV-Cre and n=12 mice for F/+; PV-Cre; two-tailed Student’s t test). F/+; SST-Cre
mice showed no change in the amount of time spent with the novel object versus
the familiar object, whereas +/+; SST-Cre mice interacted more with the novel
object (+/+; SST-Cre: ***p<0.0001; F/+; SST-Cre: p=0.7009; n=12 mice for +/+;
SST-Cre and n=8 mice for F/+; SST-Cre; two-tailed Student’s t test). b. +/+; PVCre and F/+; PV-Cre mice exhibited similar latencies to fall during both the
training and testing phases of the rotarod test (d1: p=0.4500; d2: p=0.6978; d3:
p=0.3718; d4: p=0.2056; d5: p=0.5397; d6: p=0.6487; d7: p=0.5175; d8:
p=0.4032; d9: p=0.4076; d10: p=0.2905; d11: p=0.4571; d12: p=0.5813; n=8
mice for +/+; PV-Cre and n=8 mice for F/+; PV-Cre; repeated measures ANOVA).
c. F/+; SST-Cre mice showed a decreased latency to fall during the rotarod test
from day 2 to day 12 (d1: p=0.1556; d2: ***p<0.0001; d3: ***p<0.0001; d4:
***p<0.0001; d5: ***p=0.0004; d6: ***p<0.0001; d7: ***p<0.0001; d8:
***p<0.0001; d9: ***p<0.0001; d10: ***p<0.0001; d11: ***p<0.0001; d12:
***p<0.0001; n=8 mice for +/+; SST-Cre and n=8 mice for F/+; SST-Cre;
repeated measures ANOVA). Data shown are mean ± SEM.
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To test spatial learning and reference memory, we next performed the Morris
water maze test. During the 10-day training phase, F/+; PV-Cre mice showed similar
latencies to the hidden platform as control mice (Fig. 2.8a). In a probe trial to assess
spatial memory following training, F/+; PV-Cre mice crossed the platform location a
similar number of times as controls (Fig. 2.8b, c). These mice also showed no difference
in the total swimming distance or speed (Fig. 2.8c). F/+; SST-Cre mice showed similar
latencies to the platform compared to controls for the first three days of training, but then
exhibited higher latency times throughout the remainder of the training phase (Fig. 2.8d).
Thus, F/+; SST-Cre mice may have an ability to initiate the learning process, but the
capacity of further spatial learning appears to be limited. They crossed the platform
location fewer times compared to controls during the probe trial (Fig. 2.8e, f). No
difference was observed in the total swimming distance or speed, verifying that these
factors did not contribute to the decrease in platform crosses (Fig. 2.8f). Together, these
results suggest that SST-specific Arid1b haploinsufficiency, but not the PV-specific
Arid1b loss, leads to several cognitive impairments.
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Figure 2.8 Dysfunctional spatial learning and memory in F/+; SST-Cre mice
a. The training phase of the Morris water maze test showed no change in latency
to the platform in F/+; PV-Cre mice compared to control mice (d1: p=0.2811; d2:
p=0.2898; d3: p=0.4904; d4: p=0.7700; d5: p=0.5078; d6: p=0.8765; d7:
p=0.6736; d8: p=0.4795; d9: p=0.2874; d10: p=0.3262; n=8 mice for +/+; PV-Cre
and n=8 mice for F/+; PV-Cre; repeated measures ANOVA). b. Representative
swim paths of +/+; PV-Cre and F/+; PV-Cre mice during a probe trial after
training. c. During a probe trial, F/+; PV-Cre mice showed no change in the
number of platform crosses, average velocity, or total distance traveled
compared to controls (platform crosses: p=0.4776; average velocity: p=0.7694;
distance traveled: p=0.8522; n=8 mice for +/+; PV-Cre and n=8 mice for F/+; PVCre; two-tailed Student’s t test). d. F/+; SST-Cre mice showed an increased
latency to the platform from day 4 to day 10 during the training phase of the
Morris water maze test (d1: p=0.6765; d2: p=0.1794; d3: p=0.2084; d4:
***p<0.0001; d5: ***p<0.0001; d6: ***p<0.0001; d7: ***p<0.0001; d8:
***p<0.0001; d9: ***p<0.0001; d10: ***p<0.0001; n=8 mice for +/+; SST-Cre and
n=8 mice for F/+; SST-Cre; repeated measures ANOVA). e. Representative
swim paths of +/+; SST-Cre and F/+; SST-Cre mice during a probe trial after
training. f. During a probe trial, F/+; SST-Cre mice showed fewer platform
crosses compared to control mice, while average velocity and total distance
traveled were unchanged (platform crosses: **p=0.0037; average velocity:
p=0.5127; distance traveled: p=0.5982; n=8 mice for +/+; SST-Cre and n=8 mice
for F/+; SST-Cre; two-tailed Student’s t test). Data shown are mean ± SEM.
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2.5 Discussion
2.5.1 Interneurons play a significant role in the pathology of Arid1b haploinsufficiencyinduced ASD and ID
Arid1b haploinsufficiency causes ASD and ID, leading to a broad range of
neurobehavioral phenotypes in humans and rodents (Celen et al., 2017; Halgren et al.,
2012; Hoyer et al., 2012; Jung et al., 2017; Santen et al., 2012a; Shibutani et al., 2017).
Given the abnormal anatomy and physiology of interneurons as a major hallmark of
Arid1b haploinsufficiency (Jung et al., 2017), we hypothesized that interneurons play a
critical role in mediating Arid1b haploinsufficiency-induced cognitive, social, and
emotional impairments. The heterogenous nature of the interneuron population led us to
investigate the contributions of the two most populous interneuron subtypes, PV and
SST, to the behavioral phenotypes associated with Arid1b haploinsufficiency. Our results
suggest that PV and SST interneurons contribute distinct, complementary aspects of the
major ASD- and ID-like phenotypes in Arid1b+/- mice. F/+; PV-Cre and F/+; SST-Cre
mice recapitulate the major deficits induced by Arid1b haploinsufficiency (Table 2.1).
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Behavior

Arid1b+/-

F/+; PV-Cre

F/+; SST-Cre

Social behavior

↓

↓

-

Stereotyped behavior

↑

-

↑

Anxiety

↑

↑

-

Depression

↑

↑

-

Recognition memory

↓

-

↓

Motor learning

↓

-

↓

↓

-

↓

Spatial reference
memory

Table 2.1 Summary of behavioral deficits
PV and SST interneurons contribute complementary aspects of the ASD and ID phenotypes seen
with Arid1b haploinsufficiency.
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2.5.2 Excitatory/Inhibitory imbalance in neurodevelopmental disorders
Perturbation of the well-balanced excitatory and inhibitory components can lead
to life-long cognitive, social, and emotional disabilities. Impairments in inhibitory
interneuron development and function have been implicated in several
neurodevelopmental conditions including ASD and ID (Fatemi et al., 2009; Jamain et al.,
2008; Oblak et al., 2011; Piton et al., 2013; Tabuchi et al., 2007; Zhang et al., 2009),
Rett syndrome (Chen et al., 2001; Guy et al., 2001), Schizophrenia (Chen et al., 2010),
Angelman syndrome (Wallace et al., 2012), and fragile X syndrome (Curia et al., 2009;
Gibson et al., 2008; Selby et al., 2007). Particularly, it has been increasingly evident that
PV or SST interneurons are dysfunctional in ASD and ID. Several studies have shown a
reduction of PV interneurons in rodent models of ASD and ASD-related disorders, such
as Fmrp, Mecp2, and Nlgn3 knockout mice (Fukuda et al., 2005; Gogolla et al., 2009;
Selby et al., 2007). Two mouse models of ASD, Shank1 and Cntnap4 knockout, also
exhibit reduced levels of PV interneuron output (Karayannis et al., 2014; Mao et al.,
2015). Furthermore, post-mortem brains of patients with ASD and ID show fewer PV
interneurons within the cerebral cortex (Hashemi et al., 2017; Zikopoulos and Barbas,
2013). Altered functional networks within the cortex of human patients has also been
shown, indicated by a decrease in baseline gamma-band power in the cortex during
developmental stages. As PV interneurons play a pivotal role in the generation of
gamma oscillations, it has been implicated that deficits in PV neuron development
contributes to the aberrant gamma responses (Kuki et al., 2015; Newson and
Thiagarajan, 2018; Takahashi et al., 2017). Fewer SST neurons within the cerebral
cortex has also been found in a Pten knockout mouse model of ASD (Vogt et al., 2015).
It is likely that the anatomical or functional impairments of these interneurons cause the
excitatory/inhibitory imbalance, resulting in abnormal neurobehaviors.
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2.5.3 Arid1b haploinsufficiency in PV and SST interneurons have distinct effects on
social, emotional, and cognitive behaviors
Although inhibitory interneurons are implicated in neurodevelopmental pathology,
it has been unclear whether their subtypes play unique roles in distinct neural behavior.
In this study using Arid1b mouse models, we show that PV interneurons are strongly
associated with social behavior deficits, a core feature of ASD. These results are
consistent with previous studies showing a prominent role of PV neurons in social
behavior. Pvalb knockout mice display social behavior deficits and reduced vocalizations
(Wohr et al., 2015). Reducing inhibitory output by knocking out an NMDA receptor
specifically in PV neurons also results in reduced sociability in mice (Saunders et al.,
2013). In addition, we show a prominent role of PV interneurons in emotional behavior.
Recent studies support this finding as chemogenetic manipulation of PV interneurons
modulates anxiety and depression behavior (Chen et al., 2019; Zou et al., 2016). An
autism mouse model by maternal immune activation also shows that PV neuron
dysfunction leads to elevated anxiety and depression (Canetta et al., 2016). Our results
show no clear association between SST interneurons and emotional behavior. However,
previous studies have reported that SST interneurons are involved in anxiety and
depression (Engin et al., 2008; Fuchs et al., 2017a; Fuchs et al., 2017b; Lin and Sibille,
2015). In post-mortem examination of humans with major depressive disorder, there is
reduced expression of SST in the prefrontal cortex (Seney et al., 2015; Tripp et al.,
2011). In addition, Sst knockout mice show elevated anxiety and depression (Lin and
Sibille, 2015). There are some possibilities for the contradicting results. First, a loss or
reduction of SST might have a more dramatic effect on SST neurons, whereas
haploinsufficiency of the Arid1b gene in SST cells could result in less potency on the
interneuron activity. It is likely that Arid1b haploinsufficiency elicits a different
downstream mechanism than removing the SST peptide. Also, expression of the Arid1b
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gene could be different in interneuron subtypes and brain regions. In areas strongly
associated with emotional behavior, such as the amygdala and pre-frontal cortex, Arid1b
may be expressed at a lower level compared to other regions.
We further show that cognitive dysfunction in the Arid1b haploinsufficient
condition is primarily modulated by SST interneurons. Studies have revealed the
prominent role of SST interneurons in various cognitive functions. The SST subtype
controls disinhibition of principle cells in the hippocampus, regulating sensory
processing, learning, and memory (Artinian and Lacaille, 2018). This subtype also
inhibits distal dendrites of principal neurons in layer 1 of the motor cortex to regulate
changes in excitatory synapses during motor learning (Celen et al., 2017). SST neurons
in the prefrontal cortex maintains working memory during a delay phase (Kim et al.,
2016). In contrast, PV neurons play no significant role in maintaining working memory,
but they have a stronger response in reward processing during the choice phase (Kim et
al., 2016). Studies have also shown that signaling downstream of the SST peptide in
interneurons affects learning and memory. For example, knockout of the Type 3
somatostatin receptor (Sstr3) or Type 2 somatostatin receptor (Sstr2) gene inhibits SST
signaling, which results in impaired object recognition memory (Einstein et al., 2010) or
spatial learning and reference memory (Dutar et al., 2002), respectively. Additionally,
fear conditioning studies support the contribution of SST neurons to cognitive behaviors.
Classical fear conditioning of a whisker stimulus results in increased activity of SST
neurons in the corresponding area of the barrel cortex (Cybulska-Klosowicz et al., 2013;
Gierdalski et al., 2001). Contrary to SST neurons, PV cells show no change in the barrel
cortex activity during fear conditioning (Siucinska and Kossut, 2006). These findings
suggest distinct contributions of different interneurons to neural behaviors. Indeed, there
is a recent study in which the Rett syndrome gene Mecp2 is engineered to be deleted in
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either PV or SST interneurons (Ito-Ishida et al., 2015). Loss of Mecp2 function in PV or
SST interneurons shows non-overlapping effects on motor/sensory coordination,
learning and memory, social interaction, and stereotyped behaviors in the mouse
models.
Arid1b+/- mice exhibited a reduction in overall body weight (Celen et al., 2017;
Jung et al., 2017; Shibutani et al., 2017). It is suggested that Arid1b haploinsufficiency
causes deficits in the growth hormone-releasing hormone—growth hormone—insulinlike growth factor (GHRH-GH-IGF) axis, ultimately affecting growth control (Celen et al.,
2017). Knockout mouse models of other chromatin remodelers such as BAF53B exhibit
similar deficits in body growth control (Lopez and Wood, 2015; Ronan et al., 2013). In
the current study, we see no major changes in body weight in either F/+; PV-Cre or F/+;
SST-Cre mice, suggesting no significant role of PV-specific or SST-specific Arid1b
haploinsufficiency in growth control.
2.5.4 Conclusion and future prospective
There is no treatment tool available for the core symptoms of ASD and ID.
Current pharmacologic strategies focus on GABAergic modulation to normalize inhibitory
activity. GABA agonists to enhance inhibition, such as benzodiazepines and
anticonvulsants, have been helpful in alleviating aggressive and hyperactive behaviors
associated with ASD in humans (Belsito et al., 2001; Di Martino and Tuchman, 2001).
Use of clonazepam, a positive modulator of the GABAA receptor, to enhance inhibitory
activity has also successfully rescued behavioral phenotypes in mouse models of ASD
and ID (Han et al., 2012; Jung et al., 2017). A prominent shortcoming of these strategies
is that they are currently not subtype-specific to inhibitory neurons. As we continue to
gain a better understanding of how individual interneuron subtypes modulate distinct
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behaviors in ASD and/or ID, therapeutic strategies could become even more targeted,
with greater efficacy and fewer side effects as a result.
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3.1 Abstract
Proper neurite outgrowth during development of the cerebral cortex is crucial for
establishing proper circuitry and mediating normal behavior. Deficits in neurite
development via neurotrophin signaling pathways have been implicated in
neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual
disability (ID). Recent studies have shown that haploinsufficiency of the AT-rich
interactive domain-containing 1B (ARID1B) gene is a genetic cause of ASD and ID in
humans. While behavioral aspects of these neurodevelopmental disorders are well
characterized, the underlying neuropathogenesis remains largely unknown. Here we
examine the effects that Arid1b deletion has on the developing brain using a previously
developed Arid1b knockout mouse model. We show that cultured cortical neurons
exhibit marked reduction in neurite outgrowth with loss of Arid1b. Additionally, Arid1b
knockout mice have improper development of the axon fibers comprising the corpus
callosum, a feature frequently observed in patients. Heterozygous brains also showed
reduced levels of BDNF neurotrophin signaling activity, and normalization of signaling
was able to rescue the observed neurite outgrowth deficits. Our results indicate a critical
role of ARID1B in mediating proper neurite outgrowth during brain development and
suggest a possible role of ARID1B in the BDNF signaling pathway. This insight into the
underlying pathogenesis of these disorders will hopefully pave the way for potential
genetic or pharmacologic therapeutic targets.
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3.2 Introduction
Autism spectrum disorder (ASD), which affects approximately 1 in 68 individuals
worldwide, is characterized primarily by stereotyped behaviors and social and
communication deficits (Ellison et al., 2013; Halgren et al., 2012). Nearly 75% of
individuals with ASD are also diagnosed with intellectual disability (ID), exhibiting severe
limitations in cognitive and adaptive behaviors (Daily et al., 2000; Hoyer et al., 2012).
While the behavioral features of these disorders are well characterized, the underlying
neuropathogenesis is largely unknown, and thus no pharmacologic or genetic
interventions are currently available. Current treatment for ASD and ID are primarily
limited to behavioral, occupational, and physical therapies until further research identifies
potential causative factors and therapeutic targets.
Deficits in excitatory neuron development have been implicated in
neurodevelopmental disorders (Kast and Levitt, 2019). Development of excitatory
neurons in the rodent cerebral cortex consists of three primary stages. Initially, neural
progenitors differentiate into an immature neuron, followed by migration through the
cortex to its final location, and finally neurite outgrowth (Azzarelli et al., 2014; Barnes
and Polleux, 2009). These neurites eventually become the axons and dendrites that
comprise the complex circuitry of the brain, mediating proper neurotransmission and
communication among brain regions (Tsaneva-Atanasova et al., 2009). Several mouse
models of ASD/ID and related disorders have deficits in the neurite outgrowth stage of
development, exhibiting abnormal dendritic arborization and reduced axon growth and
branching (Gilbert and Man, 2017; Irwin et al., 2002; Jiang et al., 2013; Kaufmann and
Moser, 2000). Disruptions in brain-derived neurotrophic factor (BDNF) signaling, a key
regulator of neurite outgrowth, is also prevalent among these disease states. Altered
glycogen synthase kinase 3 (GSK3) and mammalian target of rapamycin (mTOR)
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activity, two downstream components in BDNF signaling, frequently accompanies
impaired neurite outgrowth and ASD/ID-like behavioral deficits in mouse models (Jiang
et al., 2005; Morita and Sobue, 2009; Zhou et al., 2004). Furthermore, several studies
indicate that chromatin remodeling is a crucial player in regulating various stages of
cortical development. Specifically, mutations in various components of the Brg1/Brmassociated factor (BAF) chromatin remodeling complex lead to altered neurite
development in the rodent cortex (Bachmann et al., 2016; Choi et al., 2015; Weinberg et
al., 2013).
Recent progress in genetic studies has revealed that haploinsufficiency of the
AT-rich interactive domain-containing 1B (ARID1B) gene, a component of the BAF
chromatin remodeling complex, is a genetic cause of ASD and ID in humans (Halgren et
al., 2012; Hoyer et al., 2012; Santen et al., 2012a). Our lab has previously developed an
Arid1b knockout mouse model and demonstrated that Arid1b heterozygotes, which
resemble haploinsufficiency seen in human patients, exhibit severe cognitive, social, and
emotional impairments that recapitulate other models of ASD and ID (Jung et al., 2017).
While loss of Arid1b results in significant behavioral deficits, its effect in the developing
brain is still unknown. Based on the prevalence of neurite outgrowth deficits in
neurodevelopmental disorders and the key involvement of neurotrophin signaling in
regulating this process, we hypothesized that ARID1B affects neurite development via
neurotrophin signaling activity. In this study, we indeed demonstrate a key role of
ARID1B in mediating proper neurite outgrowth in the developing brain, and we propose
a possible role of ARID1B in the BDNF neurotrophin signaling pathway. Our findings
suggest that these neurite outgrowth deficits may contribute to the behavioral
impairments seen in ASD and ID.
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3.3 Materials and methods
3.3.1 Mice
Generation of Arid1b knockout mice was described previously (Jung et al., 2017).
Thy1-YFP-H mice were purchased from the Jackson Laboratory (B6.Cg-Tg(Thy1YFP)HJrs/J; JAX 003782) and crossed with Arid1b heterozygous mice to generate YFPexpressing knockout mice. After weaning, all mice were group housed (no more than 5
mice per cage) as a mix of genotypes on a 12-hour light/dark cycle. All husbandry and
experimental procedures were reviewed and approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Nebraska Medical Center.
3.3.2 Plasmids
We generated two short hairpin (sh) ARID1Bs using two different targeting
sequences (5’-GGAACCAGTTATGACCGAAGGC-3’ and 5’GCAAGTCAAAGGACAGCTATG-3’) and their complement sequences. The oligomers
were cloned into a modified pSuper-Basic vector or pLVX-shRNA2 vector (Clontech), as
previously described (Kim et al., 2006). For controls, non-silencing shRNAs were
generated using scrambled targeting sequences (5’-GACGACTGCGACGGGATAATA-3’
and 5’-GAATACGACCGACACCTACTA-3’).
3.3.3 Primary neuron cultures and growth factor treatment
Primary neuron cultures were done as described previously (Jung et al., 2017;
Ka et al., 2016a). Cortical neurons were isolated from embryonic day 14-6 (E14-E16)
mice. Meninges were removed and cortical cells were dissociated with tituration after
trypsin/EDTA treatment. The cells were plated onto poly-D-lysine/laminin-coated
coverslips and cultured for 6 DIV in a medium containing Neurobasal medium
(Invitrogen), 2 mM glutamine (Invitrogen), 2% (v/v) B27 supplement (Invitrogen), 1%
(v/v) N2 supplement (Invitrogen), and 50 U/ml penicillin/streptomycin (Invitrogen). In
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cultures that underwent treatment for the rescue experiment, 1 µl of either 50 ng/ml
BDNF, 25 nM Gsk3 inhibitor, 50 ng/ml IGF, or 4 µg/ml SC79 were added to wells at day
3 in vitro.
3.3.4 In utero electroporation
In utero electroporation was performed as described previously (Ka et al.,
2016a). Timed pregnant female mice from E14.5 gestation were deeply anesthetized,
and the uterine horns were gently exposed. The lateral ventricles of an embryonic brain
were injected with plasmid DNA (2 µg/µl), encoding either shARID1B or control shRNA,
using a Picospritzer II (Parker Inc.). Electroporation was achieved by placing two sterile
forceps-type electrodes on opposing sides of the uterine sac around the embryonic head
and applying a series of short electrical pulses using a BTX ECM 830 electroporator (five
pulses with 100 ms length separated by 900 ms intervals were applied at 45 V). The
small electrical pulses drive charged DNA constructs into surrounding cells in the
embryonic brain. Embryos were then allowed to develop in utero and be birthed
normally.
3.3.5 Immunostaining
Immunostaining of brain sections or dissociated cells was performed as
described previously (Jung et al., 2017; Ka et al., 2016a). Primary antibodies used were
chicken anti-MAP2 (PhosphoSolutions), mouse anti-pNF-H (BioLegend), chicken antiGFP (AVES), and rabbit anti-RFP (Chemicon). Appropriate secondary antibodies
conjugated with Alexa Fluor dyes (Invitrogen) were used to detect primary antibodies.
DAPI (Sigma-Aldrich) was used to stain nuclei.
3.3.6 Morphometry
Morphometric analysis was performed as described previously (Jung et al., 2017;
Ka et al., 2016a). For quantifying numbers and lengths of neurites in cultures, at least 20
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cells from different fields of view were selected at random per embryo brain and imaged
with a Zeiss LSM710 confocal microscope. Images were analyzed using ImageJ (NIH).
Primary, secondary, and tertiary axon and dendrite numbers and lengths were
measured. Cells from a single embryo were averaged for a single value for that animal,
and the values from all animals of a genotype were averaged to calculate the mean. N
numbers for each experiment are described in figure legends. To quantify corpus
callosum thickness and mean fluorescent intensity, images of five different brain
sections at periodic distances along the rostrocaudal axis were taken with the Zeiss
LSM710 confocal microscope and analyzed with ImageJ. Corpus callosum thickness
and the mean fluorescent intensity of RFP- or YFP-labeled fibers from the five sections
were averaged and reported as values for one mouse, and values from all animals in a
genotype were averaged to calculate the mean. N values for each experiment are
described in figure legends. Some results were recalculated as relative changes versus
control.
3.3.7 Western blot analysis
Western blotting was performed as described previously (Jung et al., 2017; Ka et
al., 2016a). Cellular lysates from E14-E16 brain cortices were prepared using RIPA
buffer and the protein content was determined by a Bio-Rad Protein Assay system.
Proteins were separated on a 4-12% SDS-PAGE gradient gel and transferred onto a
nitrocellulose membrane. The membrane was incubated with mouse anti-ARID1B
(Abcam), rabbit anti-p-AKT (Cell Signaling), rabbit anti-AKT (Cell Signaling), mouse antip-GSK3β (Upstate), mouse anti-GSK3 (BD Transduction Laboratory), rabbit anti-pmTOR (Cell Signaling), rabbit anti-mTOR (Cell Signaling), or mouse anti-GAPDH
(Millipore) at 4°C overnight. Appropriate secondary antibodies conjugated to HRP were
used (Cell Signaling Technology) and the ECL reagents (GE Healthcare Bio-Sciences)
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were used for immunodetection. For quantification of band intensity, blots from three
independent experiments for each molecule of interest were used. Signals were
measured using ImageJ software (NIH) and averages from the three blots are reported.
GAPDH was used as an internal control to normalize band intensity.
3.3.8 Statistical analysis
Normal distribution was tested using the Kolmogorov-Smirnov test and variance
was compared. Unless otherwise stated, statistical significance was determined using
two-tailed unpaired Student’s t tests for two-population comparisons or ANOVA followed
by Bonferroni’s post hoc test for multiple comparisons. Data were analyzed using
GraphPad Prism and were presented as the means ± SEM. P values for each
comparison are described in the figure legends. To determine and confirm sample sizes
(N), we performed a power analysis. The values for statistical power (1-β) and type I
error rate (α) were 0.8 and 0.05 (or 0.01), respectively. Each experiment in this study
was performed blind and randomized. Animals were assigned randomly to the various
experimental groups, and data were collected and processed randomly. The allocation,
treatment, and handling of animals were the same across study groups. Control animals
were selected from the same liter as the test group. The individuals conducting the
experiments were blinded to group allocation and allocation sequence. Exclusion criteria
for mice were based on abnormal health conditions, including weights below 20% of the
intergroup and intragroup average and noticeably reduced activity or feeding.
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3.4 Results
3.4.1 Loss of Arid1b disrupts neurite outgrowth in developing cortical neurons
To determine the effect of Arid1b deletion on neurite outgrowth, we first cultured
cortical neurons from Arid1b+/+, Arid1b+/-, and Arid1b-/- embryos and labeled cells with
anti-pNF-H and anti-MAP2 antibodies, markers for axons and dendrites, respectively.
We then quantified the numbers and lengths of primary, secondary, and tertiary axons
and dendrites. Both Arid1b+/- and Arid1b-/- neurons showed a decrease in secondary and
tertiary axon numbers compared to Arid1b+/+ controls, with no change in primary axon
number (Fig. 3.1a,b). Primary, secondary, and tertiary axon lengths were also decreased
in Arid1b+/- and Arid1b-/- neurons compared to controls (Fig. 3.1a,c). Additionally,
Arid1b+/- and Arid1b-/- also showed a reduction in primary, secondary, and tertiary
dendrite number compared to controls (Fig. 3.2a,b). No significant changes in dendrite
lengths were observed (Fig. 3.2a,c). These results indicate that deletion of the Arid1b
gene impairs outgrowth and branching of axons and dendrites in developing cortical
neurons. It also appears that Arid1b deletion may exhibit a more prominent effect on
axons compared to dendrites. Future experiments we will focus solely on Arid1b
heterozygous mice, as they best recapitulate ARID1B haploinsufficiency in the human
condition. Arid1b-/- mice are also lethal after birth, and therefore cannot be used on any
postnatal experiments.
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Figure 3.1 Impaired axon growth in neurons with Arid1b deletion
a. Representative images of cultured neurons from all three mouse genotypes
with axons labeled with pNF-H. White arrow heads indicate primary, secondary,
or tertiary axons. b. Quantification of the number of primary, secondary, and
tertiary axon numbers (secondary: ***P<0.001 for Arid1b+/+ vs. Arid1b+/- and
Arid1b+/+ vs. Arid1b-/-; tertiary: ***P<0.001 for Arid1b+/+ vs. Arid1b+/- and Arid1b+/+
vs. Arid1b-/-). c. Quantification of primary, secondary, and tertiary axon lengths
(primary: **P<0.01 for Arid1b+/+ vs. Arid1b+/-, ***P<0.001 for Arid1b+/+ vs. Arid1b-/; secondary: **P<0.01 for Arid1b+/+ vs. Arid1b+/-, ***P<0.001 for Arid1b+/+ vs.
Arid1b-/-; tertiary: ***P<0.001 for Arid1b+/+ vs. Arid1b+/-, **P<0.01 for Arid1b+/+ vs.
Arid1b-/-). The number of embryos used was N=6 for each genotype. Significance
was determined across genotypes using one-way ANOVA with Bonferroni’s posthoc correction. Data shown are mean +/- SEM.
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Figure 3.2 Impaired dendrite growth in neurons with Arid1b deletion
a. Representative images of cultured neurons from all three mouse genotypes
with dendrites labeled with MAP2. White arrow heads indicate primary,
secondary, or tertiary dendrites. b. Quantification of the number of primary,
secondary, and tertiary dendrite numbers (primary: ***P<0.001 for Arid1b+/+ vs.
Arid1b+/- and Arid1b+/+ vs. Arid1b-/-; secondary: **P<0.01 for Arid1b+/+ vs.
Arid1b+/-, ***P<0.001 for Arid1b+/+ vs. Arid1b-/-; tertiary: ***P<0.001 for Arid1b+/+
vs. Arid1b+/- and Arid1b+/+ vs. Arid1b-/-). c. Quantification of primary, secondary,
and tertiary dendrite lengths. The number of embryos used was N=6 for each
genotype. Significance was determined across genotypes using one-way
ANOVA with Bonferroni’s post hoc correction. Data shown are mean +/- SEM.
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3.4.2 Impaired corpus callosum development with Arid1b deletion
To confirm that loss of Arid1b has the same effect on neurite development in
vivo, we examined axons in cortical mouse brain sections. A neural deficit frequently
seen in human patients with ARID1B haploinsufficiency is agenesis of the corpus
callosum (Halgren et al., 2012; Santen et al., 2012a), so we specifically examined axon
fibers comprising the corpus callosum. We first performed in utero electroporation to
incorporate Arid1b shRNA into the brains of mouse embryos. Adult mice injected with
Arid1b shRNA exhibited a reduction in fluorescent intensity of axon fibers within the
midline region of the corpus callosum compared to mice injected with control shRNA,
implying fewer axon fibers comprising the corpus callosum (Fig. 3.3a,b). In addition,
mice with Arid1b shRNA had decreased fluorescent intensity of axon fibers in the lateral
regions of the corpus callosum as well as altered fiber direction, indicated by an increase
in the number of fiber cross points, compared to control mice (Fig. 3.3c,d). Together,
these results indicate that knockdown of Arid1b alters the development of white matter
axon fibers in the cortex, in particular the corpus callosum. Since shRNA knockdown
results in inconsistent gene dosage, we also wanted to examine the corpus callosum
effects on Arid1b heterozygous knockout mice. Arid1b+/- mice were crossed with a Thy1YFP-H mouse, resulting in Arid1b+/- mice with YFP-labeled callosal fibers. Arid1b+/-; YFP
mice showed a decrease in midline corpus callosum thickness and a reduction in axon
fiber fluorescent intensity compared to Arid1b+/+; YFP control mice (Fig. 3.3e,f),
confirming a role of ARID1B in mediating proper corpus callosum development.
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Figure 3.3 Abnormal corpus callosum development in with loss of Arid1b
a. Representative images of medial corpus callosum axon fibers labeled with
RFP in adult mice injected with either shARID1B or control shRNA. b.
Quantification of the mean fluorescence intensity of midline axon fibers
comprising the corpus callosum (*P<0.05 for control vs. shARID1B). c.
Representative images of lateral corpus callosum axon fibers labeled with RFP
in adult mice injected with either shARID1B or control shRNA. d. Quantification
of the mean fluorescence intensity of axon fibers comprising the lateral region of
the corpus callosum (**P<0.01 for control vs. shARID1B) and the number of
axon crosses within the lateral region of the corpus callosum (***P<0.001 for
control vs. shARID1B). The number of animals used was N=5 each for mice
injected with control shRNA and mice injected with shARID1B. e. Representative
images of medial corpus callosum axon fibers labeled with YFP in adult (4 wk)
Arid1b+/+ and Arid1b+/- mice. f. Quantification of the total corpus callosum
thickness at the midline (***P<0.001 for Arid1b+/+ vs. Arid1b+/-) and the mean
fluorescence intensity of midline axon fibers (***P<0.001 for Arid1b+/+ vs.
Arid1b+/-). The number of animals used was N=6 for each genotype. Significance
for all experiments was determined using two-tailed unpaired Student’s t tests.
Data shown are mean +/- SEM.
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3.4.3 Arid1b deletion alters neurite development via BDNF signaling activity
BDNF neurotrophin signaling is a key regulator in multiple stages of neuron
development, including neurite outgrowth (Jiang et al., 2005; Morita and Sobue, 2009;
Zhou et al., 2004). To determine whether ARID1B plays a role in this signaling pathway,
we first examined protein expression levels of key signaling components. Arid1b+/mouse brain cortices showed a decrease in the level of phosphorylated forms of protein
kinase B (Akt) and its downstream targets mTor and Gsk3β compared to wild type
controls, with no change in levels of non-phosphorylated forms, indicating altered activity
of this pathway (Fig. 3.4a,b). These results suggest a possible role of ARID1B upstream
of AKT in the neurotrophin signaling pathway in regulating neurite outgrowth.
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Figure 3.4 Arid1b heterozygous mice exhibit reduced BDNF neurotrophic
signaling activity
a. Representative images of western blots showing reduced phosphorylation of
proteins in the BDNF neurotrophic signaling pathway in Arid1b+/- mouse cortices.
b. Quantification of a. The band intensity of each protein was normalized to
GAPDH levels (ARID1B: **P<0.01; p-AKT: **P<0.01; p-mTOR: ***P<0.001; pGSK3β: ***P<0.001). 3 independent experiments were done using 3 mice per
genotype, and significance was determined using two-tailed unpaired Student’s t
tests. Data shown are mean +/- SEM.
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We then wanted to determine whether normalizing this pathway activity in
Arid1b-deficient neurons to wild type levels could rescue the neurite outgrowth deficits
seen previously. To do this, we treated cultured neurons with various molecules to
normalize BDNF signaling activity. We analyzed the total number and length of axons
and dendrites after treatments with each of the following: SC79 (an AKT protein
activator), BDNF (a growth factor acting on the TrkB receptor), IGF-1 (a growth factor
acting on the TrkB receptor), and GSK3-i (a GSK3 inhibitor). Each treatment showed a
rescue of the total axon number and length as well as total dendrite number in Arid1b+/mouse neurons to wild type levels (Fig. 3.5a-d). Together, these results demonstrate
that normalization of the BDNF signaling pathway in Arid1b-deficient mice rescues the
impaired neurite outgrowth seen with loss of Arid1b, suggesting a possible mechanistic
role of ARID1B in this pathway.
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Figure 3.5 Normalizing BDNF signaling levels rescued neurite outgrowth deficits in
Arid1b heterozygotes
a. Representative images of cultured neurons from Arid1b+/+ and Arid1b+/- embryos treated
with SC79, BDNF, IGF-1, GSK3-i, or no treatment. Axons are labeled with pNF-H. b.
Quantification of the total number of axons (***P<0.001 for Arid1b+/+ control vs. Arid1b+/control; ###P<0.001 for Arid1b+/- control vs. Arid1b+/- + SC79; ###P<0.001 for Arid1b+/- control
vs. Arid1b+/- + BDNF; ###P<0.001 for Arid1b+/- control vs. Arid1b+/- + IGF-1; ###P<0.001 for
Arid1b+/- control vs. Arid1b+/- + GSK3-i) and total axon lengths (***P<0.001 for Arid1b+/+
control vs. Arid1b+/- control; ##P<0.01 for Arid1b+/- control vs. Arid1b+/- + SC79; ###P<0.001 for
Arid1b+/- control vs. Arid1b+/- + BDNF; ###P<0.001 for Arid1b+/- control vs. Arid1b+/- + IGF-1;
###P<0.001 for Arid1b+/- control vs. Arid1b+/- + GSK3-i) following each treatment. c.
Representative images of cultured neurons from Arid1b+/+ and Arid1b+/- embryos treated with
SC79, BDNF, IGF-1, GSK3-i, or no treatment. Dendrites are labeled with MAP2. d.
Quantification of the total number of dendrites (***P<0.001 for Arid1b+/+ control vs. Arid1b+/control; ###P<0.001 for Arid1b+/- control vs. Arid1b+/- + SC79; ###P<0.001 for Arid1b+/- control
vs. Arid1b+/- + BDNF; ###P<0.001 for Arid1b+/- control vs. Arid1b+/- + IGF-1; ###P<0.001 for
Arid1b+/- control vs. Arid1b+/- + GSK3-i) and total dendrite lengths following each treatment.
For both axon and dendrite rescue experiments, 4 embryos per genotype were used for
each treatment group. Significance was determined using one-way ANOVA with Bonferroni’s
post hoc correction. Data shown for all experiments are mean +/- SEM.
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3.5 Discussion
3.5.1 Proposed pathology underlying neurite deficits in ARID1B haploinsufficiency
Haploinsufficiency of ARID1B, a genetic cause of ASD and ID, causes several
behavioral phenotypes and anatomical changes in humans and rodents (Celen et al.,
2017; Halgren et al., 2012; Hoyer et al., 2012; Jung et al., 2017; Santen et al., 2012a;
Shibutani et al., 2017). Given the prevalence of neurite deficits in these disorders
(Chapleau et al., 2009; Fiala et al., 2002; Kaufmann and Moser, 2000; Machado-Salas,
1984; Penzes et al., 2011) and the prominent role of chromatin remodeling during
neurodevelopment (Day and Sweatt, 2011; Mehler, 2008; Ronan et al., 2013), we
hypothesized that ARID1B deletion disrupts neurite growth during excitatory cortical
neuron development. In the present study, we indeed show that deletion of Arid1b leads
to deficits in neurite development of cortical neurons and suggest a potential mechanism
of ARID1B in the BDNF signaling pathway. During proper development of the cortex,
BDNF signaling mediates downstream phosphorylation of mTOR and GSK3β, which
subsequently activate several proteins associated with cytoskeletal dynamics (Barnes
and Polleux, 2009; Hur and Zhou, 2010; Yoshimura et al., 2005). Precise organization of
actin and microtubules is the basis of the mechanism mediating neurite outgrowth and
branching (Barnes and Polleux, 2009; Lewis et al., 2013). Figure 3.6 illustrates the
potential pathology underlying altered neurite development in ARID1B
haploinsufficiency. We suggest that loss of ARID1B, likely acting upstream of AKT,
reduces BDNF signaling activity and ultimately disrupts the downstream actin and
microtubule dynamics mediating neurite outgrowth.
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Figure 3.6 A potential role of ARID1B in the BDNF neurotrophic pathway
regulating neurite outgrowth
a. A proposed role of ARID1B upstream of AKT in the BDNF signaling pathway,
leading to normal cytoskeletal dynamics and proper neurite outgrowth. b. Loss of
ARID1B in neurons leads to reduced phosphorylation of downstream AKT, mTOR,
and GSK3β, resulting in altered cytoskeletal dynamics and impaired neurite
outgrowth.
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3.5.2 Neurite development and neurotrophic signaling deficits in various
neurodevelopmental disorders
Our lab has previously shown that loss of Arid1b has a significant effect on
inhibitory interneuron development (Jung et al., 2017). Jung et al. observed that Arid1b
deletion led to fewer interneurons, abnormal interneuron placement, and reduced
interneuron synaptic activity. Further, pharmacologic activation of interneuron activity
successfully rescued several of the behavioral deficits associated with loss of the gene
(Jung et al., 2017). However, in addition to deficits in interneuron development, several
human patients and animal models of ASD, ID, and related disorders implicate deficits in
neurite growth of excitatory neurons. For example, post-mortem brains of patients with
ASD and Rett syndrome, a neurodevelopmental disorder characterized by autism- and
ID-like traits, exhibit abnormal dendritic arborization and atypical genesis of the corpus
callosum axon tracts (Armstrong, 2005; Belichenko et al., 1994; Halgren et al., 2012;
Huttenlocher, 1974; Santen et al., 2012a). Mouse models of ASD, including knockout of
Taok2 and Ankrd11 genes, have similar deficits in dendrite formation and axonal
projections (de Anda et al., 2012; Ka and Kim, 2018). Mecp2 knockout mice, a model for
Rett syndrome, also exhibit abnormal dendritic outgrowth due to altered microtubule
dynamics (Nectoux et al., 2012). Additionally, several mouse models of ASD/ID, Rett
syndrome, and fragile X syndrome have decreased levels of BDNF signaling and
reduced expression of downstream targets accompanying deficits in neuron maturation
(Cao et al., 2013; Chang et al., 2006; Jung et al., 2016). Together, these studies
contribute to the growing evidence that deficits in neurite development via disrupted
neurotrophic signaling have pathogenic roles in neurodevelopmental disorders.
3.5.3 Conclusion and future prospective
Therapeutic tools to treat the core symptoms of ASD and ID are severely lacking.
While the behavioral phenotypes of these disorders have been well defined,
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pharmacologic treatments are not currently available. By better understanding the
various mechanisms that underlie the pathology of neurodevelopmental disorders, we
can determine potential pharmacologic therapeutic targets. We expect that the deficits in
neurite outgrowth leads to altered connectivity among brain regions and likely contribute
to the behavioral phenotypes seen with ARID1B haploinsufficiency-associated ASD and
ID. Further research to elucidate the precise mechanism of ARID1B may lead to
potential therapeutic targets within the BDNF signaling pathway.
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CHAPTER 4: DISCUSSION AND CONCLUSIONS
The above chapters have discussed two major roles of ARID1B in the pathology
of neurodevelopmental disorders such as autism spectrum disorder and intellectual
disability. This section will summarize each chapter and discuss their implications for the
field and future research avenues.
Previous work in our lab has shown that Arid1b haploinsufficiency leads to
deficits in cortical interneuron development, suggesting disruption in the E/I balance.
Mice with loss of one copy of Arid1b had fewer interneurons, abnormal interneuron
distribution, and impaired inhibitory synaptic activity (Jung et al., 2017). Additionally,
these mice exhibited several behavioral phenotypes consistent with ASD and ID,
including social impairments, stereotyped behaviors, elevated anxiety and depression,
and cognitive dysfunction (Jung et al., 2017). In the study presented in Chapter 2, we
sought to elucidate the functional diversity among interneuron subtypes that contribute to
various behavioral phenotypes seen with Arid1b haploinsufficiency. It is well established
that interneuron classes are highly diverse and heterogenous (Kepecs and Fishell, 2014;
Lim et al., 2018; Rudy et al., 2011), but little is known regarding how each subtype may
modulate behaviors. Interestingly, we show that Arid1b haploinsufficiency in either PV or
SST interneurons led to distinct behavioral phenotypes that did not overlap with one
another, but recapitulated the phenotypes seen with global haploinsufficiency. Loss of
Arid1b in PV interneurons had prominent effects on social behavior and anxiety- and
depression-like behavior, while loss of Arid1b in SST interneurons primarily affected
stereotyped behaviors and cognitive function.
Our conclusions from Chapter 2 suggest that the different subtypes of
interneurons distinctly modulate behaviors. This insight will be valuable in moving
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forward with developing novel therapeutic options for neurodevelopmental disorders.
While the focus on normalizing inhibitory interneuron activity is a promising therapeutic
technique, this method is currently non-specific and targets all interneurons in the brain.
By better defining the specific behavioral roles of interneuron subtypes, pharmacologic
and genetic treatments can be more targeted to modulate only certain subsets of cell
types. It is important for future studies to continue to elucidate the distinct behavioral
roles of interneuron subtypes in other neurodevelopmental disorder mouse models.
ARID1B haploinsufficiency accounts for less than 1% of individuals with ASD and ID
(Halgren et al., 2012; Hoyer et al., 2012; Krumm et al., 2014; Ropers and Wienker, 2015;
Santen et al., 2012a; Santen et al., 2012b). While this may seem insignificant in the big
picture of diagnosed individuals, it is likely that several causal genes converge on
common pathways and exhibit similar underlying pathology. Indeed, most ASD/IDassociated genes are a part of one of three major classes: chromatin remodeling,
transcriptional control, and synaptic structure and function (Ayhan and Konopka, 2019;
Krumm et al., 2014). Further, several human patients and mouse models exhibit similar
deficits in interneuron development and function (Marin, 2012; Ramamoorthi and Lin,
2011; Robertson et al., 2016). It will be interesting to see how our results compare to
similar studies done with other models. Similar findings of distinct behavioral roles of
interneurons may be promising for future therapies for a range of neurodevelopmental
disorders.
In the study from Chapter 3, we examined the potential role of ARID1B in the
development of excitatory projection neurons in the cortex. Excitatory neuron
development occurs in three primary stages: proliferation/differentiation, migration, and
neurite outgrowth (Azzarelli et al., 2014; Barnes and Polleux, 2009; Lalli, 2014). Each of
these steps are important for proper brain circuity and synaptic connections. Disruption
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of any of these processes may affect how information is transmitted throughout the
brain, therefore altering normal behavior. Previous studies in our lab show no changes in
number, distribution, or synaptic function of excitatory neurons within the cortex of
Arid1b-deficient mice, suggesting proliferation/differentiation or migration issues are not
causing any significant deficits within these cell types (Jung et al., 2017). While Jung et
al. do report minor deficits in proliferation and apoptosis, these do not appear have any
lasting affect that alters the excitatory neuron makeup of the mature cortex. It is possible
that a compensatory mechanism normalizes these stages so there is still proper number
and distribution of these neurons throughout the cortex.
Studies indicate that deficits in neurite outgrowth are frequently observed in
mouse models and human patients of ASD and related disorders (Belichenko et al.,
1994; Huttenlocher, 1974; Jiang et al., 2013; Kaufmann and Moser, 2000). Additionally,
Jung et al. demonstrated that treatment of Arid1b heterozygous mice with a GABAergic
modulator to normalize inhibitory activity was successful in rescuing ASD- and ID-like
behavioral phenotypes (Jung et al., 2017). However, not all behavior deficits were
completely rescued to wild type levels, suggesting a potential pathological role of
excitatory neurons in addition to inhibitory interneurons. As excitatory neurons are
responsible for several long-range projections to various brain regions, it would be
reasonable to suggest that deficits in axon and dendrite development will affect
communication between cells and alter normal behavior. This led us to examine neurite
outgrowth in Arid1b-deficient excitatory neurons and the potential role that ARID1B plays
in the process. We showed that loss of Arid1b led to deficits in neurite outgrowth and
branching as well as altered corpus callosum development. Since BDNF neurotrophic
signaling is a known master regulator of neurite growth and is disrupted in various
neurodevelopmental disorders (Jiang et al., 2005; Morita and Sobue, 2009; Zhou et al.,

100
2004), we sought whether ARID1B may be playing a role in this particular pathway. We
indeed showed that neurite deficits were accompanied by altered BDNF signaling, and
normalization of this pathway was successful in rescuing these deficits. Interestingly,
while BDNF signaling regulates axon/dendrite specification as well as neurite outgrowth,
our data still show a single axon with multiple dendrites. This suggests that the deficits
resulting from loss of BDNF signaling are affecting neurite growth without affecting
polarity. It is possible that loss of BDNF signaling activity triggers a compensatory
mechanism that normalizes the polarity specification stage during development, or that
the level of activity was still sufficient to properly establish polarity. It is also possible that
the BDNF signaling pathway was disrupted at a specific developmental time point after
polarity has been established. It would be important in the future to determine the
precise developmental stage at which BDNF signaling is disrupted.
Our results from Chapter 3 suggest a novel role of ARID1B in the development of
projection neurons in the cerebral cortex, indicating a possible avenue for pharmacologic
or genetic treatment targets. Further study is necessary to elucidate the precise
mechanism of ARID1B. For example, the use of ChIP assays can determine whether
ARID1B is directly interacting with and regulating gene expression of any components in
BDNF signaling. It may also be beneficial to examine how Arid1b loss affects BDNF
signaling at different developmental stages and in different subcellular compartments to
determine if there is a spatiotemporal regulatory component. Given that cytoskeleton
dynamics are the basis of the mechanism mediating neurite outgrowth, it would be
interesting to examine how loss of Arid1b affects the cytoskeleton during neurite growth
via time lapse imaging. Previous studies have been successful in rescuing neurotrophic
signaling deficits by microinfusion of BDNF into the ventricles of adult mice, which led to
rapid phosphorylation of downstream components (Ying et al., 2002). This ability to
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rescue BDNF signaling in vivo is an exciting avenue for future research in the treatment
of neurodevelopmental disorders with neurotrophic signaling deficits.
Overall, results presented in this dissertation shows significant progress in the
various roles of ASD/ID-associated gene ARID1B in the development of the cerebral
cortex. This insight into the underlying pathogenesis of neurodevelopmental disorders
paves the way for future studies and brings to light new questions. The field has come a
long way in discovering novel therapies for the treatment of neurodevelopment
disorders. Pharmacologic techniques to modulate GABAergic activity and neurotrophic
signaling is a promising treatment approach given the high incidence of interneuron
dysfunction and BDNF signaling deficits. Genetic tools have also become a promising
treatment approach. Gene therapy via AAV-mediated delivery has shown success in
several animal models and human patients of neurological disorders (Hocquemiller et
al., 2016). However, utilizing this strategy as a successful therapy for
neurodevelopmental disorders will likely be limited by a critical developmental window
for treatment. Additionally, success in genome editing via the CRISPR/Cas system in
reprogramming pluripotent stem cells indicates a theoretical possibility of utilizing this
strategy in the treatment of neurological diseases (Yang and Huang, 2019). There are
still several ethical considerations that need attention before this strategy can be
considered a plausible avenue. Gaining a more complete understanding of the
mechanisms of ARID1B and other genes involved with neurodevelopment will enhance
the individualization of novel therapies for those affected with neurodevelopmental
disorders. Furthermore, dissecting individual cell types and specific circuits that regulate
pathogenic behaviors will make more targeted therapies with fewer side effects more
feasible.
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